UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                 ---------------
                                   FORM 10-KSB

            |X| ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                   FOR THE FISCAL YEAR ENDED DECEMBER 31, 2006

                                       OR

          |_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
               FOR THE TRANSITION PERIOD FROM _____ TO __________

                            COMMISSION FILE NO. 09081

                                   CYBRDI INC.
             ------------------------------------------------------
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

            CALIFORNIA                                     95-2461404
   -------------------------------                     -------------------
   (STATE OR OTHER JURISDICTION OF                      (I.R.S. EMPLOYER
    INCORPORATION OR ORGANIZATION)                     IDENTIFICATION NO.)

      401 ROSEMONT AVE. FREDERICK, MD                          21701
     ---------------------------------------                ----------
     (ADDRESS OF PRINCIPAL EXECUTIVE OFFICE)                (ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:       (301) 644-3901


      ---------------------------------------------------------------------
               Former name, former address and former fiscal year,
                         (if changed since last report)

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act Yes [ ] No [X]

Indicate by check mark if the Registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities and Exchange Act 0f 1934
during the preceding 12 months (of for such shorter period that the registrant
was required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No[ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendments to
this Form 10-k.

<PAGE>

Indicate by a check mark whether the registrant is a large accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Indicate by a check mark whether the registrant is a shell Company (as defined
by Rule 12b-2 of the Act). Yes [ ] No [X]

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of
Common Stock as of the latest practicable date: 50,456,569 shares of Common
Stock, without par value, as of March 31, 2007.

State issuer's revenues for its most recent fiscal year ended December 31, 2006:
$542,286

The aggregate market value of the voting and non-voting common equity held by
non-affiliates computed by reference to, as of March 31, 2007 was approximately
$1,652,007 based on a closing bid price of $0.04 and a total of 41,300,172
shares held by non-affiliates.

APPLICALBE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY

                           (PROCEEDINGS DURING THE PRECEDING FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Section 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court.

                       Yes [ ]     No [ ]     Not Applicable [X]

DOCUMENTS INCORPORATED BY REFERENCE:

None


<PAGE>


                               TABLE OF CONTENTS

                                                                           PAGE
                                                                           ----
PART I

ITEM 1      Description of Business                                           3
ITEM 2      Description of Property                                           9
ITEM 3      Legal Proceedings                                                 9
ITEM 4      Submission of matters to a vote of security holders              10

PART II

ITEM 5      Market For Common Equity and Related Stockholder Matters         10
ITEM 6      Management Discussion and Analysis                               11
ITEM 7      Selected Financial Data                                          11
ITEM 8      Financial Statements                                             15
ITEM 9A     Changes In And Disagreements With Accountants Accounting And
            Financial Disclosures                                            15
ITEM 9B     Controls and Procedures                                          16
ITEM 9C     Other Information                                                16

PART III

ITEM 10     Directors, Executive Officers, Promoters And Control Persons,
            Compliance With Section 16(A) Of The Exchange Act.               16
ITEM 11     Executive Compensation                                           18
ITEM 12     Certain Relationships and Related Transaction                    20
ITEM 13     Exhibits                                                         20
ITEM 14     Principal Accounting Fees and Services                           21

This annual report contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These include statements
about our expectations, beliefs, intentions or strategies for the future, which
we indicate by words or phrases such as "anticipate," "expect," "intend,"
"plan," "will," "we believe," "our company believes," "management believes" and
similar language. These forward-looking statements are based on our current
expectations and are subject to certain risks, uncertainties and assumptions,
including those set forth in the discussion under Item 1. "Description of
Business" and Item 6. "Management's Discussion and Analysis", including under
the heading "- Risk Factors" under Item 6. Our actual results may differ
materially from results anticipated in these forward-looking statements. We base
our forward-looking statements on information currently available to us, and we
assume no obligation to update them. In addition, our historical financial
performance is not necessarily indicative of the results that may be expected in
the future and we believe such comparisons cannot be relied upon as indicators
of future performance.

Certain financial information included in this annual report has been derived
from data originally prepared in Renminbi (RMB), the currency of the People's
Republic of China ("China" or "PRC"). For purposes of this annual report,
conversion at year-end exchange rates of US$1.00 to RMB 7.8041 for assets and
liabilities, and weight average rate US$1.00 to RMB7.923 for revenue and
expenses in year 2006. There is no assurance that RMB amounts could have been or
could be converted into US dollars at that rate.

Please see Note 3 summary of significant accounting policy item (l) for Foreign
currency translation

                                       2
<PAGE>

PART I

ITEM 1.  DESCRIPTION OF BUSINESS

HISTORY

Our company, Cybrdi, Inc. ("we", "us", "our", "Cybrdi" or "our company"), was
incorporated under the laws of the State of California in 1966. On April 2, 2005
we filed amendments to the articles of incorporation to change our name from
Certron Corporation to Cybrdi, Inc. The amendment was approved by the required
vote of shareholders in accordance with Section 902 and Section 903 of the
California Corporations Code.

Until around June 2004, the Company's business consisted primarily of the
distribution of magnetic media products, primarily blank audio and video
cassettes. Due to continuing intense price competition and technological changes
in the marketplace for its products, the Company lost its remaining significant
customers and disposed of or wrote off its remaining inventory. As a result of
these occurrences, the Company concluded that it's audio and videotape
businesses were no longer viable and some of its product lines were obsolete and
the Company placed its emphasis on attempting to find a buyer for the Company.

In November 2004, the Company, through Certron Acquisition Corp., a newly formed
Maryland corporation and wholly-owned subsidiary of the Company ("Acquisition
Sub") acquired all of the issued and outstanding shares of common stock of
Cybrdi, Inc., a privately held company incorporated in the State of Maryland
("Cybrdi Maryland"). The Company acquired all of the issued and outstanding
shares of common stock of Cybrdi Maryland in exchange for 47,328,263 shares of
common stock of the Company. Subsequent to the merger, the former shareholders
of Cybrdi Maryland were the owners of approximately 93.8% of the outstanding
shares of the Company's common stock.

With the completion of the merger, all the magnetic media distribution business
activities have ceased and Cybrdi's focus is the field of biogenetics
commercialization, specializing in the rapid introduction of tissue microarray
products and services in both the international and Chinese markets.

Most of our activities are conducted through our 80% equity ownership in China
Shaanxi Chaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a sino-foreign
equity joint venture established in July 2000 in the People's Republic of China.
Our plan is to capitalize China's huge population with our quality tissue
microarray and other products. We have also been exploring business
opportunities that could leverage our existing sales distribution channel and
relationship with our affiliated companies.

Our operating revenues decreased from $1,427,799 to $542,286 in 2006, and we
incurred a net loss of $187,055 as compared to net income of $5,128 in 2006.
Please refer to Item 6. "Management's Discussion and Analysis".

BUSINESS OVERVIEW

Most of Cybrdi's activities are conducted through its 80% equity ownership in
China Shaanxi Chaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a
sino-foreign equity joint venture established in July 2000 in the People's
Republic of China. Cybrdi became affiliated with Chaoying Biotech in March 2003.
The Chaoying Biotech joint venture agreement has a term of 15 years. The term of
joint venture may be extended upon the mutual consent of the parties.

We focus on biogenetics commercialization and healthcare product applications.
Our primary business includes sales of tissue microarray products and services.
Tissue chips, also called microtissue arrays, represent a newly developed
technology providing high-throughput molecular profiling and parallel analysis
of biological and molecular characteristics for hundreds of pathologically
controlled tissue specimens. Tissue arrays can provide rapid and cost-effective
localization and evaluation of proteins, RNA, or DNA molecules, which is
particularly useful for functioning genomic studies. Cybrdi manufactures both
human and animal tissue microarray for a wide variety of scientific uses,
including drug discovery and development purposes.

Our principal operations are located in Shaanxi China. Our Maryland company
focuses primarily on business development of tissue microarrays in North America
and Europe.

While we continue to market and develop our products, management has determined
to place any of its cash that is not immediately required for its future growth
or operations with non-affiliated third party borrowers. These are short-term
unsecured loan obligations that enable the Company to generate interest revenue
at a rate that is significantly higher than those available from Chinese banks.
Sour our Financial Statements and Item 6 for a more detailed description.

                                       3
<PAGE>

THE EMPLOYEES

As of December 31, 2006, we had approximately 51 full-time employees (employees
in China, and 1 in Maryland).

THE PRODUCTS

TISSUE MICROARRAYS (TMAS)

We manufacture both human and animal tissue microarrays for a wide variety of
scientific uses, including drug discovery and development purposes. TMA
technology can survey hundreds or even thousands of clinical specimens in a
single experiment utilizing common probes, including DNA, RNA, peptide, protein
and antibody probes. This is an efficient, in vivo approach for the validation
of gene discoveries and identification of potential molecules for diagnosis and
therapy.

Chaoying Biotech owns an 18,000 square foot, approximately 2000 m 2, in Shaanxi,
China which includes a manufacturing facility and a pathology and molecule
laboratory. We have established the standard tissue chip production, processing
procedure and quality control system in our facility. We have also established
an electronic management system to effectively manage biologic information
databank.

We currently offer a wide variety of tissue array products and services on the
commercial market, including approximately (at present) 122 different disease
and 84 different organ types of both human and animal varieties. These tissues
are prepared in a variety of array panels of differing formats and tissue
densities to service the full range of scientific research interests. New
products are being added on a monthly basis per customer demands.

TMA chips can be broadly applied in both basic and clinical research conducted
by the academic, medical, pharmaceutical and biogenetic research communities.
Our customers include pharmaceutical companies, biotechnology companies and
research institutes, such as Merck, Genentech, Chiron, Astrozenic, Wyeth, NIH
and Cancer Centers.

TECHNICAL SERVICES

Complementing the production and marketing of tissue chips, we have launched an
in-house technical services platform to perform customized research according to
customer specifications. By outsourcing experimentation to us, international
research labs, (particularly those in high labor and material cost markets) can
incur substantial cost savings. Frequently requested services include the
standard immunohisto chemistry (IHC) and in-situ-hybridization (ISH) services
needed to locate proteins or genes of interest using customer-supplied probes.
These probes are applied to select normal, diseased and marginal tissue from our
tissue array bank. The results are presented as publishable, detailed pathology
reports including high resolution digital photographs. Through virtual
cybernetic bio-services (vCBS), these results can be sent via the Internet to
the customer the day after the probe is received by our labs. Our technical
services currently serves our Chinese customers.

Due to increased competition in China, tighter credit policies, and our clients
receiving reduced funding from the Chinese government, our technical service
sector has experienced declines in revenues in China during the year 2006.

MARKET OPPORTUNITIES AND COMPETITION

CHINA BIOTECH TRENDS

Biotechnology research has been supported by the Chinese government; becoming a
designated key industry in China's scientific development plan in 1986. However,
most biotech investment has been made in the areas of basic research in
government funded laboratories or government linked companies focused on major
scientific discoveries in gene function. Cybrdi received a government grant of
$56,263 (U.S. equivalency) and $12,168 (U.S. equivalency) in 2006.

MARKETING STRATEGIES

China Market: By leveraging existing hospital relationships and Shaanxi
Chaoying's, marketing channels, we have marketed TMA products, medical care
products and other services within the China market. We have two primary
regional focuses in China, the Northern provinces which include the cities of
Beijing, Tian Jing and Hebei Province, and the eastern provinces which include
the cities of Shanghai, Zhejiang Province and Shangdong Province. We market and
intend to market our product and services through our own direct sales efforts
and by utilizing independent distributors.

International Marking Strategy: By leveraging our know-how and infrastructure of
China operations, we are attempting to expand international distribution


                                       4
<PAGE>

channels. We currently have distributors in the US, Canada, Germany, Italy,
Belgium, Japan and Taiwan. While we see further opportunities in North America,
Europe and other Chinese markets, our current focus will be on existing
distribution channels.

COMPETITION

Our TMA products are facing increased competition. While the high costs and
strict patient information protocol associated with tissue collection in most
developed economies make it difficult for companies with competing products of
similar quality to compete, cost differences are narrowing. Furthermore,
established genomics firms such as Ambion and Clinomics outsource most TMA
production yet are beginning to offer the wide product series variety demanded
by the global research community. This presents increased price and service
competition for us under either in-house and/or through OEM programs.

At the other end of the price spectrum, low-priced tissue chips are providing
better quality and adequate density. The production of qualified TMAs requires
expertise in several scientific areas including pathology, immunology, molecular
and biology. Producers of TMA must also meet in hygienic standards, quality
controls, and special materials processing and shipping procedures not only in
the country of manufacture but for usage in the country of ultimate destination.
In addition, because of the high cost of reliable commercial TMAs, and,
conversely, the low quality of low cost TMAs, many research institutions had
previously established their own production teams for in-house research needs
prior to the introduction of our TMAs.


INTELLECTUAL PROPERTY

We regard our service marks, trademarks, trade secrets, patents and similar
intellectual property as critical to our success. We rely on patent, trademark
and trade secret law, as well as confidentiality and license agreements with
certain of our employees, customers and others to protect our proprietary
rights. Currently we own four invention patents:

<TABLE>
<CAPTION>
----------------------------------------------- --------------------------- ------------------------------
                NAME OF PATENT                        NUMBER OF PATENT              AWARDED TIME
----------------------------------------------- --------------------------- ------------------------------
<S>                                                    <C>                       <C>
Tissue Microarrays (TMAs)                              ZL01128783.7                 June 1st 2005
----------------------------------------------- --------------------------- ------------------------------
A way to test content of special antibody in
body fluid in a certain part                           ZL01131756.6              December 15th 2004
----------------------------------------------- --------------------------- ------------------------------
Diabetes   autoimmune   antibody   test   kit
multiplex Chip, equipment and method                   ZL02145561.9              November 17th 2004
----------------------------------------------- --------------------------- ------------------------------
Diabetes immunization antibody testing
protein chips and its own preparation,
detection methods                                      ZL02145535.X               October 27th 2004
----------------------------------------------- --------------------------- ------------------------------
</TABLE>

RESEARCH AND DEVELOPMENT

Our strategy is to incrementally advance from our current technological base
into complementary, rapidly commercialized products and services. New product
development can represent an expansion of existing TMA technical knowledge or a
new commercial application of current knowledge.

We currently perform all of our own research and development activities. We have
our own research; development and laboratory facilities located at our Shanxi
facility and retain our own professional research and development team. We may
enter into agreements for research and development activities with third parties
in the future.

We plan to continue to enhance research and development in TMAs and technical
service by expanding our virtual tissue array data bank (vTMAB) to meet expected
growing demand from various research institutions and medical universities and
colleges. Offering our products and services on a price competitive basis will
be a key to meeting this growing market demand.

Our strategic focuses in the near future also include the biotechnology
cosmetics and healthcare products, and health diagnosis for obesity and skin
disease.

AVAILABLE INFORMATION

Information regarding the Company's annual reports on Form 10-K or Form 10-KSB,
quarterly reports on Form 10-QSB or Form 10-Q, current reports on Form 8-K, and
any amendments to these reports, are available to the public from the SEC's


                                       5
<PAGE>

website at http://www.sec.gov as soon as reasonably practicable after the
Company electronically files such reports with the Securities and Exchange
Commission. Any document that the Company files with the SEC may also be read
and copied at the SEC's public reference room. Please call the SEC at
1-800-SEC-0330 for further information on the public reference room. We will
also supply this information to any shareholder requesting copies of any of the
foregoing free of charge. Shareholders should contact our office at
(301)644-3901 if they desire copies of any of our filings with the Securities
and Exchange Commission.

RISK FACTORS

You should consider each of the following risk factors and any other information
set forth in this Form 10-KSB and our other reports that we have filed with the
Securities and Exchange Commission ("SEC"), including the Company's financial
statements and related notes, in evaluating the Company's business and
prospects. The risks and uncertainties described below are not the only ones
that impact on the Company's operations and business. Additional risks and
uncertainties not presently known to the Company, or that the Company currently
considers immaterial, may also impair its business or operations. If any of the
following risks actually occur, our business and financial condition, results or
prospects could be harmed.

RISKS ASSOCIATED WITH THE COMPANY'S PROSPECTIVE BUSINESS AND OPERATIONS

The Company has a limited history with respect to the manufacture, sale and
distribution of TMAs. Medical technology is constantly evolving and there can be
no assurance that our TMAa will keep pace with medical breakthroughs. The
Company's ability to achieve and maintain profitability and positive cash flow
over time will be dependent upon, among other things, its ability to (i)
continue to develop new TMA products and market these products both in China and
other developing companies and (ii) its ability to evaluate the merits of
pursuing the beauty supply business and its success in developing franchise
opportunities despite no prior experience.

OUR BUSINESS IS HEAVILY DEPENDENT ON THE ECONOMIC GROWTH OF CHINA

At the current time, our business is heavily dependent on the economy and
developing middle and upper class in China. Should the country suffer an
economic downturn or should the government imposed restrictions on the growth of
private companies and the ability of a large consumer class to earn money in the
private sector our business will suffer. To the extent that any of the foregoing
should occur, our revenues will decline significantly.

WE HAVE LOANED OVER $3 MILLION TO NON-AFFILIATED THIRD PARTIESS

In order to maximize returns on available cash, the Company has outstanding
unsecured loans totaling approximately $3.2 million, representing approximately
69% of the Company's assets. The loans were placed to secure additional interest
income. However, in the event of a default, the Company risks substantial loss
of their ability to continue to finance ongoing operations. Litigation could be
costly to enforce the loan obligations and may deprive the Company of the use of
the cash for a significant period of time.

RELIANCE ON SINGLE CUSTOMER

We generated approximately 31.8% of our revenues from sales to a single
customer. Should this customer face financial difficulty, refuse to pay our
invoices as they become due or, direct their business to a competitor, our
business operations will suffer.

WE MAY NOT BE ABLE TO SUPPORT OUR OPERATIONS THROUGH INTERNAL GROWTH

In order to fully implement our business plan, we may require additional
financing. Financing may be in the form of traditional bank financing or through
the sale of our common stock. There can be no assurance that we will be able to
secure adequate bank financing or if available, will be on terms acceptable to
the Company. If we attempt to sell shares of our common stock, existing
shareholders will face dilution and likely a reduction in the price of our
common stock. There are currently no financing arrangements in place.

OUR BUSINESS MAY BE AFFECTED BY UNEXPECTED CHANGES IN REGULATORY REQUIREMENTS IN
THE JURISDICTIONS IN WHICH WE OPERATE.

Development and distribution of our TMA's is subject to regulation both where we
manufacture and where we sell the products. We believe that we are currently in
compliance with applicable governmental rules and procedures. However, there can
be no assurance that changes in the regulatory environment will not make it
difficult for us to comply or result in a substantial increase in our operating
costs and a resulting decline in our margins.

                                       6
<PAGE>

THERE IS UNCERTAINTY AS TO OUR ABILITY TO CONTROL COSTS AND EXPENSES.

If our business grows, costs will increase. Management cannot accurately project
or give any assurance, with respect to its ability to control development and
operating costs and/or expenses in the future. Consequently, even if the Company
is successful in expanding its operations (of which there can be no assurance),
our management still may not be able to control costs and expenses adequately,
and therefore such expansion may result in operating losses. Likewise, if we
have reduced revenues like we had this past year, there can be no assurance that
we will be able to reduce our expenses to offset any decline in revenues.

COMPETITION

Our market is highly competitive and some of our competitors may have greater
resources than us. These competitors may be able to respond more quickly to new
or emerging technologies and changes in customer requirements and devote greater
resources to develop, promote and sell their services. If this should occur,
revenues may decline and we will likely lose market share.

IF WE DO NOT MANAGE OUR GROWTH, WE MAY NOT BE ABLE TO OPERATE OUR BUSINESS
EFFECTIVELY.

We expect significant expansion will be required to address potential growth in
our customer base, the breadth of our service offerings, and other
opportunities. This expansion could strain our management, operations, systems
and financial resources. To manage any future growth of our operations and
personnel, we must improve and effectively utilize operational, management,
marketing and financial systems and successfully recruit, hire, train and manage
personnel and maintain close coordination among our technical, finance,
marketing, sales and recruitment staffs. We also will need to manage an
increasing number of complex relationships with customers, strategic partners,
advertisers and other third parties. Our failure to manage growth could disrupt
our operations and ultimately prevent us from generating the revenue we expect.

UNANTICPATED OBSTACLES TO EXECUTION OF OUR BUSINESS PLAN.

The Company's business plans may change significantly. Many of the Company's
potential business endeavors are capital intensive and may be subject to
statutory or regulatory requirements. Management believes that the Company's
chosen activities and strategies are achievable in light of current economic and
legal conditions with the skills, background, and knowledge of the Company's
principals and advisors. Management reserves the right to make significant
modifications to the Company's stated strategies depending on future events.

CERTAIN POLITICAL AND ECONOMIC CONSIDERATIONS RELATING TO THE PRC COULD
ADVERSELY AFFECT OUR COMPANY.

The government of the People's Republic of China has welcomed foreign investment
and the expansion of business opportunities in the private sector. There can be
no assurance that this policy will continue or alternatively, that this policy
will not be modified to make it more restrictive to transfer funds from China to
the United States or any other country. Moreover, political instability could
adversely impact our ability to fully implement our business plan as political
instability would likely lead to a downturn in the Chinese economy.

CURRENCY EXCHANGE

Changes in the exchange rate of the Chinese yuan renminbi (CYN) may adversely
impact our profitability. If the CYN declines with respect to the U. S. dollar,
our profitability will be adversely affected.

RESEARCAH AND DEVELMENT CAN BE COSTLY

Medical advances are taking place at a rapid pace. In order to stay competitive,
and bring state of the art TMAs to the market at competitive prices will require
us to continue to devote significant resources to research and development.
There can be no assurance that we will have sufficient cash flow to make this
commitment on a going forward basis.

                                       7
<PAGE>

RELIANCE ON CURRENT MANAGEMENT

We are reliant on our current management team to help us fully implement our
business plan. The loss of any of their services could have a material adverse
impact on the implementation of our business plan and our future growth. We do
not carry any type of key man insurance. During this past year, Dr. Liu resigned
as a director for personal reasons. Dr, Liu is in charge of our activities in
Maryland and will continue to run our US operations. We have not yet filled this
vacancy on our Board of Directors.

The Company's business may experience periods of rapid growth that will place
significant demands on its managerial, operational and financial resources. In
order to manage this possible growth, the Company must continue to improve and
expand its management, operational and financial systems and controls. The
Company will need to expand, train and manage its employee base. No assurances
can be given that the Company will be able to timely and effectively meet such
demands.

WE MAY HAVE DIFFICULTY ATTRACTING TALENT IN FOREIGN COUNTRIES.

Our research and development program requires us to recruit highly skilled
personnel. There can be no assurance that we will be able to attract these
personnel for work either in the United States or China. If we cannot attract
skilled personnel, our operations will likely suffer and any competitive edge
that we have in the marketplace will quickly erode.

CORPORATE GOVERNANCE MATTERS

We have not voluntarily implemented various corporate governance measures in the
absence of which, shareholders may have more limited protections against
interested director transactions, conflicts of interest and similar matters.

Recent Federal legislation, including the Sarbanes-Oxley Act of 2002, has
resulted in the adoption of various corporate governance measures designed to
promote the integrity of the corporate management and the securities markets.
Some of these measures have been adopted in response to legal requirements.
Others have been adopted by companies in response to the requirements of
national securities exchanges, such as the NYSE or The Nasdaq Stock Market, on
Which their securities are listed. Among the corporate governance measures that
are required under the rules of national securities exchanges and NASDAQ are
those that address board of directors' independence, audit committee oversight,
and the adoption of a code of ethics. While our board of directors has adopted a
Code of Ethics and Business Conduct, we have not yet adopted any of these other
corporate governance measures and, since our securities are not yet listed on a
national securities exchange or Nasdaq, we are not required to do so. It is
possible that if we were to adopt some or all of these corporate governance
measures, shareholders would benefit from somewhat greater assurances that
internal corporate decisions were being made by disinterested directors and that
policies had been implemented to define responsible conduct. For example, in the
absence of audit, nominating and compensation committees comprised of at least a
majority of independent directors, decisions concerning matters such as
compensation packages to our senior officers and recommendations for director
nominees may be made by a majority of directors who have an interest in the
outcome of the matters being decided. Prospective investors should bear in mind
our current lack of corporate governance measures in formulating their
investment decisions.

We may be exposed to potential risks relating to our internal controls over
financial reporting and our ability to have those controls attested to by our
independent auditors.

As directed by Section 404 of the Sarbanes-Oxley Act of 2002 ("SOX 404"), the
Securities and Exchange Commission adopted rules requiring public companies to
include a report of management on the company's internal controls over financial
reporting in their annual reports. In addition, the independent registered
public accounting firm auditing a company's financial statements must also
attest to and report on management's assessment of the effectiveness of the
company's internal controls over financial reporting as well as the operating
effectiveness of the company's internal controls.

While we expect to expend significant resources in developing the necessary
documentation and testing procedures required by SOX 404, there is a risk that
we will not comply with all of the requirements imposed thereby. At present,
there is no precedent available with which to measure compliance adequacy.
Accordingly, there can be no positive assurance that we will receive a positive
attestation from our independent auditors. In the event we identify significant
deficiencies or material weaknesses in our internal controls that we cannot
remediate in a timely manner or we are unable to receive a positive attestation
from our independent auditors with respect to our internal controls, investors
and others may lose confidence in the reliability of our financial statements
and our ability to obtain equity or debt financing could suffer.

                                       8
<PAGE>

RISKS RELATED TO THE COMPANY'S COMMON STOCK

The COMPANY DOES NOT EXPECT TO PAY CASH DIVIDENDS IN TH EFORESEEABLE FUTURE.

Company has never paid cash dividends on its common stock and has no plans to do
so in the foreseeable future. The Company intends to retain earnings, if any, to
develop and expand its business.

"PENNY STOCK" RULES MAY MAKE BUYING OR SELLING THE COMMON STOCK DIFFICULT A
SEVERELY LIMIT THEIR MARKET AND LIQUIDITY.

 Trading in the Company's common stock is subject to certain regulations adopted
by the SEC commonly known as the "Penny Stock Rules". The Company's common stock
qualifies as penny stock and is covered by Section 15(g) of the Securities and
Exchange Act of 1934, as amended (the "1934 Act"), which imposes additional
sales practice requirements on broker/dealers who sell the Company's common
stock in the market. The "Penny Stock" rules govern how broker/dealers can deal
with their clients and "penny stock". For sales of the Company's common stock,
the broker/dealer must make a special suitability determination and receive from
clients a written agreement prior to making a sale. The additional burdens
imposed upon broker/dealers by the "penny stock" rules may discourage
broker/dealers from effecting transactions in the Company's common stock, which
could severely limit its market price and liquidity. This could prevent
investors from reselling Echo common stock and may cause the price of the common
stock to decline.

Although publicly traded, the Company's common stock has substantially less
liquidity than the average trading market for a stock quoted on other national
exchanges, and our price may fluctuate dramatically in the future.

Our Common Stock is currently quoted on the Pink Sheets. Our Common Stock was
previously listed for trading on the Over-the-Counter Electronic Bulletin Board.
The trading market in the common stock has substantially less liquidity than the
average trading market for companies quoted on other national stock exchanges. A
public trading market having the desired characteristics of depth, liquidity and
orderliness depends on the presence in the marketplace of willing buyers and
sellers of our common stock at any given time. This presence depends on the
individual decisions of investors and general economic and market conditions
over which we have no control. Due to limited trading volume, the market price
of the Company's common stock may fluctuate significantly in the future, and
these fluctuations may be unrelated to the Company's performance. General market
price declines or overall market volatility in the future could adversely affect
the price of the Company's common stock, and the current market price may not be
indicative of future market prices.

ITEM 2.  DESCRIPTION OF PROPERTY

Our operations in the United States are located at 401 Rosemont Avenue FITCI
Frederick, MD 21701 where we lease approximately 2,000 square feet of space from
FITC a non-affiliated party. Our annual rental payment is $26,160 payable in
monthly increments of $2,180. The lease is on a month-by-month basis. If we are
unable to extend this lease, we do not anticipate any difficulties in locating
office space to meet our operational needs.

Our operations in the People's Republic of China are located at the Chaoying
Workshop, Third Floor, Changyanbu, Private-owned industrial zone where we use
approximately 18,000 square feet (2,000 square meters) of space. We lease office
space from a related party, Shaanxi Chaoying Beauty & Cosmetics Group Co, Inc.
We pay $5,017 per month in rent (equivalent to RMB 40,000 per month) and will
expire December 31, 2007. We believe that this arrangement is comparable to what
we would pay had we leased similar space from a non-affiliated entity. The
facility is sufficient for our current operations. Should our operations expand
and we need to locate additional rental properties, we do not anticipate any
problems in securing additional leased space.

ITEM 3.  LEGAL PROCEEDINGS

There are no materials pending legal proceedings to which we are a party. We
were notified by a letter dated June 2, 2000 received June 6, 2000 that we may
have a potential liability from waste disposal in the Casmalia Disposal Site at
Santa Barbara County, California. We were given a choice of either signing an
agreement that would toll the statute of limitations for eighteen (18) months in
order to allow us to resolve any liability with the government without incurring
costs associated with being named a defendant in a lawsuit, or becoming an
immediate defendant in a lawsuit. We signed the tolling agreement. On November
20, 2001, the tolling agreement was extended for an additional 18 months. On May
20, 2003 the tolling agreement was again extended for an additional 18 months
and on November 24, 2004 the tolling agreement was again extended for additional
18 months. On June 29, 2004, we received a proposed settlement from the EPA in
the amount of $21,131. We are waiting for communication from the government
concerning payment of the proposed settlement. As of December 31, 2005, we have
accrued a sufficient amount to cover any potential liabilities from this matter.

                                       9
<PAGE>

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted during the fourth quarter of the fiscal year
covered by this report.

PART II

ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Our current stock symbol is "CYDI.PK". Our common stock was previously quoted on
the Over-the-Counter-Bulletin Board. ("OTCBB"). Prior to our merger with Cybrdi
we traded on the OTCBB under the symbol "CRTN". Following our acquisition of
Cybrdi, Inc., we requested a symbol change and were assigned CYDI.

The following table sets forth, for the periods indicated, the range of high and
low bid quotations for our common stock as quoted on the OTCBB and the Pink
Sheets. The reported bids quotations reflect inter-dealer prices without retail
markup, markdown or commissions, and may not necessarily represent actual
transactions.

         YEAR               PERIOD                     HIGH              LOW
         ----               ------                     ----              ---
         2004               First Quarter              0.450            0.115
                            Second Quarter             0.145            0.115
                            Third Quarter              0.300            0.110
                            Fourth Quarter             0.350            0.170

         2005               First Quarter              0.900            0.200
                            Second Quarter             0.750            0.280
                            Third Quarter              0.440            0.200
                            Fourth Quarter             0.285            0.160

         2006               First Quarter              0.200            0.120
                            Second Quarter              0.10             0.07
                            Third Quarter               0.10             0.05
                            Fourth Quarter              0.06             0.05

         2007               First Quarter               0.10             0.08

(a) Transfer Agent

Our transfer agent is American Stock Transfer & Trust Company Inc., whose
address is 6201 15th Ave. Brooklyn, NY 11219 their telephone number is
(212)936-5100.

(b) Stockholders

As of March 31, 2007, there were approximately 1,333 record holders of our
common stock. As of March 31, 2007, we have not paid any cash dividends on
shares of our common stock and do not plan to do so. We currently plan to retain
future earnings to fund the development and growth of our business.

(c) Dividend Policy.

We have not declared or paid cash dividends or made distributions in the past,
and we do not anticipate that we will pay cash dividends or make distributions
in the foreseeable future. We currently intend to retain and reinvest future
earnings, if any, to finance our operations.

(d) Securities authorized for issuance under equity compensation plans

None.

                                       10
<PAGE>

ISSUANCE OF UNREGISTERED SHARES

None.

ITEM 6.  SELECTED FINANCIAL INFORMATION

Following is a summary of our operations and financial condition from 2002
through 2006. You are urged to review the detailed audited financial statements
and accompanying footnotes for a complete understanding of our operations.

<TABLE>
<CAPTION>
                              2006           2005          2004          2003          2002*
                          -----------    -----------   -----------   -----------   -----------
<S>                       <C>            <C>           <C>           <C>           <C>
Net sales                 $   546,286    $ 1,427,799   $ 1,533,043   $ 1,227,394   $   750,000
Net income (loss) from
continuing operations        (187,055)   $     5,128   $   488,833   $   260,350   $  (945,000)
Net income (loss) from
discontinued operations            --             --            --            --
Net income (loss)            (187,055)   $     5,128   $   488,833   $   260,350   $  (945,000)
Net income (loss) per
common share                    (0.00)   $      0.00   $      0.02   $      0.01   $     (.030)
Total assets              $ 5,653,841    $ 6,103,632   $ 5,737,261   $ 4,745,236   $ 1,203,000
Long-term debt                     --             --            --            --
Working capital             4,258,523    $ 4,796,714   $ 4,416,664   $ 2,628,334   $   911,000
Stockholders' equity      $ 4,159,095    $ 4,224,142   $ 4,099,661   $ 3,087,340   $ 1,065,000
</TABLE>
----------
* As a result of the ownership interests of the former shareholders of Cybrdi
  Maryland, for financial statement reporting purposes, the merger was treated
  as a reverse acquisition, with Cybrdi Maryland deemed the accounting acquirer
  and Certron Corporation deemed the accounting acquiree. Historical information
  of the surviving company is that of Cybrdi Maryland. Financial information for
  the fiscal year ended 2002 is that of Certron Corporation for information
  purposes.

No cash dividends have been paid during the five-year period ended December 31,
2006.

ITEM 7.  MANAGEMENT DISCUSSION AND ANALYSIS

This annual report contains forward-looking statements within the meaning of the
federal securities laws. These include statements about our expectations,
beliefs, intentions or strategies for the future, which we indicate by words or
phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe,"
"Cybrdi believes," "management believes" and similar language. The
forward-looking statements are based on the current expectations of Cybrdi and
are subject to certain risks, uncertainties and assumptions, including those set
forth in the discussion under "Description of Business" and "Management's
Discussion and Analysis," including the discussion under "Risk Factors"
thereunder. The actual results may differ materially from results anticipated in
these forward-looking statements. We base the forward-looking statements on
information currently available to us, and we assume no obligation to update
them.

Plan of Operations

We focus on biogenetics commercialization and healthcare product applications.
Our primary business includes sales of tissue microarray products and services.
Tissue chips, also called microtissue arrays, provide high-throughput molecular
profiling and parallel analysis of biological and molecular characteristics for
hundreds of pathologically controlled tissue specimens. Tissue arrays can
provide rapid and cost-effective localization and evaluation of proteins, RNA,
or DNA molecules, which is particularly useful for functioning genomic studies.
Cybrdi manufactures both human and animal tissue microarray for a wide variety
of scientific uses, including drug discovery and development purposes.

Our business strategy and focus in the near future include
     o   Enhancing R&D in TMAs and technical service
     o   Expanding our product portfolio and virtual tissue array data bank
         (vTMAB)
     o   Launch the health diagnosis kit for obesity and skin disease

                                       11
<PAGE>

With our sophisticated research in genes, we can provide the professional health
diagnostic service for customer. We can check the reasons of obesity and other
skin disease like freckle by our genetic analysis, which offer more accurate and
specialized diagnosis. It can guide customer to set up right health or fitness
program. At present, it is the first and only company can provide genetic test
for the mechanism of obesity or skin disease. It has large market potential.

We will also explore other business development opportunities that can leverage
our sales platform and relationship with affiliated companies. Until such time
as we can identify attractive marketing opportunities, we will loan available
cash on a short term unsecured basis to non-affiliated third parties in order to
generate interest income.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Use of Estimates: The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
materially from those estimates.

The preparation of financial statements in conformity with generally accepted
accounting principles (GAAP) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results may differ from those estimates.

Revenue recognition: Revenue represents the invoiced value of goods sold
recognized upon the delivery of goods to customers and service income is
recognized when services are provided. Deferred revenue represents the
undelivered portion of invoiced value of goods sold to customers. Sales
transactions not meeting all the conditions of the full accrual method are
accounted for using the deposit method of accounting. Under the deposit method,
all costs are capitalized as incurred, and payments received from the buyer are
recorded as customer deposits.

Principles of consolidation: The consolidated financial statements include the
accounts of Cybrdi, Inc. and its wholly-owned subsidiaries and joint ventures.

RESULTS OF OPERATIONS

YEAR ENDED DECEMBER 31, 2006 COMPARED TO YEAR ENDED DECEMBER 31, 2005

Revenues

Cybrdi generates two categories of revenues: revenues from the sale of our
tissue chip products and from services. Total revenues declined from $1,427,799
to $542,286.

Tissue Chip Product: sales declined$732,164 from $1,173,171 to $441,007, a
decline of approximately 62.41%. While sales at our U.S. based subsidiary,
increased slightly from approximately $258,028 to $271,279, revenues from China
declined from $1,169,771 to $271,007. This decrease was primarily due to the
client level of Chao Ying changed with different unit sale price involved. In
year 2005 Chao Ying sale most his products to the clients in China with the
higher unit sales price while it sale the most of its products to the clients in
USA with the lower unit sales price in the year 2006. After eliminated the
intercompany transactions between Cybrdi Inc and Chao Ying, Chao Ying sale
70.62% of its products to USA clients in year 2006 while it sales only 6.52% of
its products to USA clients in year 2005.

In year 2006, tissue chip sales in China had more competition (more competitors
added into our business field) and some former customers in China, especially
medical colleges and hospitals, have become capable of making tissue array
products by themselves. Accordingly we had decreased our sales in China with
higher unit sales price, and increased our sales to USA clients with lower unit
sales price.

Also, prior to year 2005, we advanced the credit to our customers, while we
required purchasers to prepay the sales order in year 2006. This has created a
significantly reduced demand to purchase our products. Finally government grants
to some scientific institutions have declined. With fewer funds, there has been
a decline in demand for our products

Services: Fewer technical service orders were received during 2005 as compared
to 2004 resulting in a decrease in sales from $254,628 to $101,279 or
approximately 60.22% decreased. We believe that this decline is primarily
attributable to increased competition from larger better financed multinationals
that can compete on the basis name recognition and pricing. We believe that we
will be able to compete in the future based upon the quality of service we can
provide.

                                       12
<PAGE>

Gross Margin

Gross margin as a percent of sales was 49.43% and 80.40% for the year ended
December 31, 2006 and 2005, respectively. Gross profit for the year ended
December 31, 2006 decreased to $268,072 from $1,147,961 for the year ended
December 31, 2005. The primary reason for the decrease was the gross profit of
the Company's subsidiary in PRC ("Chao Ying") has a large decreased in year
2006. This decrease was primarily due to the client level of Chao Ying changed
with different unit sale price involved. In year 2005 Chao Ying sale most his
products to the clients in China with the higher unit sales price while it sale
the most its products to the clients in USA with the lower unit sales price in
the year 2006. After eliminated the intercompany transactions between Cybrdi Inc
and Chao Ying, Chao Ying sale 70.62% of its products to USA clients in year 2006
while it sales only 6.52% of its products to USA clients in year 2005.

Operating Expenses

Despite reduced revenues, our operating expenses increased $12,062 from $682,008
to $694,070. Selling expenses increased $7,511 from $100,173 to $107,684 while
general and administrative expenses increased $4,551from $581,835 to $586,386.
The increase in general and administrative expenses was primarily due to the
increase of consulting fee and professional expenses in year 2006.The increase
in selling expenses is primary due to the membership fee increased $38,126
(RMB303,950) from $45,751 to $7,625.allocated from Tinmei Lelier Slim Body
Medical Tech for the year ended December 31, 2006 for the Company to use
Lelier's trade mark, technology and products. The effective period for this
membership is from November 10th 2005 to December 31, 2007. For the period from
November 10th 2005 (date of membership start) to December 31, 2006, the Company
did not generate any income from this membership

Other Income

We generated $173,072 in interest income in year 2006. Most of this interest
income is due to loans which we have made to QuanYe Security Co.,Ltd ("QuanYe")
, an unrelated People's Republic of China ("PRC") registered company located in
Xian PRC. QuanYe is engaged in the pawnshop business and their primary business
is offering alternative financing to small local companies. According to the
loan agreement, QuanYe has received loans from Chaoying Biotech of a total
amount of RMB29.3Million (equivalent to $3,754,437) since January 2006. As of
December 31, 2006, the loans balance had been reduced to RMB25.3 Million
(equivalent to $3,241,886). Management believes and views QuanYe as an
alternative financial institution and it is an optimal way to use its cash on
hand. The regular market interest rate in the PRC is 0.72% per annum. Cybrdi
expects to obtain higher interest income for its unused fund through these types
of loan arrangements. However, these advances are unsecured and have a default
risk higher than a bank deposit.

Income Taxes

The Company has not recorded a provision for federal income tax for year ended
December 31, 2006 due to utilization of net operating loss carry forward to
offset taxable income in United States. In accordance with the relevant tax laws
and regulations of the People's Republic of China, Chaoying Biotech is entitled
to full exemption from Corporation Income Tax ("CIT") for the first two years
and a 50% reduction in CIT for the next three years, commencing from the first
profitable year after offsetting all tax losses carried forward from the
previous five years. As 2003 was Chaoying Biotech's first profitable year, the
Company begins to record 50% CIT provision from the first quarter of 2005.
Effective tax rate is approximately 7.5% for the year ended December 31, 2006.
No taxes are due for 2006 as a result of our loss.

LIQUIDITY AND CAPITAL RESOURCES
DECEMBER 31, 2006 AS COMPARED TO DECEMBER 31, 2005

We had a working capital balance (current assets less current liabilities) of
$4,258,523 as of December 31, 2006 as compared to a working capital balance of
$4,197,126 as of December. The increase was primarily due to an increase in
loans to nonaffiliated of $3,241,886. This was partially offset by a reduction
in our cash balance from $4,206,695 to $782,899. The reduction in our cash
balance is due to management's decision to make interest bearing loans during
any period in which there was no immediate cash requirement. Property, plant and
equipment totaled $505,714 and our patents were valued at $519,415, The decrease
in property, plant and equipment is the result of accumulated depreciation and
old equipments disposal which we incurred during the year while the decrease in
our patents is the result of amortization expenses which we incurred during the
year.

Total current liabilities declined from $730,332 to $370,189. The primary reason
for this decline was the reduction in amounts due to stockholders/officers from
$645,021 to $205,218. During 2005 and 2006, these stockholders/officers made non
interest bearing loans to the Company to assist with operations.

                                       13
<PAGE>

Cash provided by operating activities was $258,210 for the year ended December
31, 2006 as compared to $181,915 for the year ended December 31, 2005.The
primary reason for this increase was our ability to collect on a number of
delinquent account receivables.

The Company had $23,335 in capital expenditure for the year ended December 31,
2006 as compared to capital spending of $30, 173 for the year ended December 31,
2005. Financing activities for the year ended December 31, 2006 includes a
$14,849 advance from a shareholder and a $454,652 return the advance back to a
shareholder.

With a working capital balance of approximately $4.2 million, the Company
believes it will have sufficient resources to finance its operations for the
coming year.

CRITICAL ACCOUNTING POLICIES

Use of Estimates: The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
materially from those estimates.

Income per share: Basic income per share excludes dilution and is computed by
dividing the income attributable to common shareholders by the weighted-average
number of common shares outstanding for the period. Diluted income per share
reflects the potential dilution that could occur if securities or other
contracts to issue common stock were exercised or converted into common stock or
resulted in the issuance of common stock that shared in the income of the
Company. Diluted income per share is computed by dividing the income available
to common shareholders by the weighted average number of common shares
outstanding for the period and dilutive potential common shares outstanding
unless consideration of such dilutive potential common shares would result in
anti-dilution. Common stock equivalents were not considered in the calculation
of diluted income per share as their effect would have been anti-dilutive for
the periods ended December 31, 2004 and 2003.

Critical Accounting Policies: The preparation of financial statements in
conformity with generally accepted accounting principles (GAAP) requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results may differ from those
estimates.

Off-Balance Sheet Arrangements: We have not entered into any off-balance sheet
arrangements. We do not anticipate entering into any off-balance sheet
arrangements during the next 12 months.

RECENT ACCOUNTING PRONOUNCEMENTS

Recent Accounting Pronouncements:

In July 2006, the Financial Accounting Standards Board (FASB) issued FASB
Interpretation (FIN) No. 48, "Accounting for Uncertainty in Income Taxes-an
interpretation of FASB Statement No. 109." This interpretation provides guidance
for recognizing and measuring uncertain tax positions, as defined in SFAS No.
109, "Accounting for Income Taxes." FIN No. 48 prescribes a threshold condition
that a tax position must meet for any of the benefit of an uncertain tax
position to be recognized in the financial statements. Guidance is also provided
regarding de-recognition, classification, and disclosure of uncertain tax
positions. FIN No. 48 is effective for fiscal years beginning after December 15,
2006. The Company does not expect that this interpretation will have a material
impact on its financial position, results of operations, or cash flows.

In September 2006, the FASB issued Statement of Financial Accounting Standards
No. 157, "Fair Value Measurements" ("FAS 157"). This Statement defines fair
value as used in numerous accounting pronouncements, establishes a framework for
measuring fair value in generally accepted accounting principles and expands
disclosure related to the use of fair value measures in financial statements.
The Statement is to be effective for the Company's financial statements issued
in 2008; however, earlier application is encouraged. The Company is currently
evaluating the timing of adoption and the impact that adoption might have on its
financial position or results of operations.

In September 2006, the SEC issued Staff Accounting Bulletin No. 108, considering
the Effects of Prior Year Misstatements when quantifying Misstatements in
Current Year Financial Statements ("SAB 108"). SAB 108 requires companies to
evaluate the materiality of identified unadjusted errors on each financial
statement and related financial statement disclosure using both the rollover
approach and the iron curtain approach, as those terms are defined in SAB 108.
The rollover approach quantifies misstatements based on the amount of the error


                                       14
<PAGE>

in the current year financial statement, whereas the iron curtain approach
quantifies misstatements based on the effects of correcting the misstatement
existing in the balance sheet at the end of the current year, irrespective of
the misstatement's year(s) of origin. Financial statements would require
adjustment when either approach results in quantifying a misstatement that is
material. Correcting prior year financial statements for immaterial errors would
not require previously filed reports to be amended. If a Company determines that
an adjustment to prior year financial statements is required upon adoption of
SAB 108 and does not elect to restate its previous financial statements, then it
must recognize the cumulative effect of applying SAB 108 in fiscal 2006
beginning balances of the affected assets and liabilities with a corresponding
adjustment to the fiscal 2006 opening balance in retained earnings. SAB 108 is
effective for interim periods of the first fiscal year ending after November 15,
2006. The adoption of SAB 108 did not have an impact on the Company's
consolidated financial statements.

In May 2005, the FASB issued Statement No. 154, "Accounting Changes and Error
Corrections" ("FAS 154"). FAS 154 generally require that accounting changes and
errors be applied retrospectively. FAS 154 is effective for accounting changes
and corrections of errors made in fiscal years beginning after December 15,
2005. The Company does not expect FAS 154 to have a material impact on its
financial statements.

In March 2005, the FASB issued Statement of Financial Accounting Standards
Interpretation Number 47, "Accounting for Conditional Asset Retirement
Obligations" ("FIN 47"). FIN 47 provides clarification regarding the meaning of
the term "conditional asset retirement obligation" as used in FASB Statement No.
143, "Accounting for Asset Retirement Obligations." FIN 47 is effective for
fiscal years beginning after December 15, 2005. The Company is currently
evaluating the impact of FIN 47 on its financial statements.

On December 16, 2004, the Financial Accounting Standards Board ("FASB")
published Statement of Financial Accounting Standards No. 123 (Revised 2004),
Share-Based Payment ("SFAS 123R"). SFAS 123R requires that compensation cost
related to share-based payment transactions be recognized in the financial
statements. Share-based payment transactions within the scope of SFAS 123R
include stock options, restricted stock plans, performance-based awards, stock
appreciation rights, and employee share purchase plans. This standard will be
effective for awards granted, modified or settled in fiscal years beginning
after June 15, 2005. Accordingly, the Company will implement the revised
standard in the first quarter of fiscal year 2006. Management is assessing the
implications of this revised standard, which may materially impact the Company's
results of operations in fiscal year 2006 and thereafter.

Other accounting standards that have been issued or proposed by the FASB or
other standards-setting bodies that do not require adoption until a future date
are not expected to have a material impact on the consolidated financial
statements upon adoption.

INFLATION

Inflation has not had a material impact on our business.

CURRENCY EXCHANGE FLUCTUATIONS

The net sales, costs and expenses generated by our activities in China are
priced in Chinese renminbi. Approximately $1.020 million of our assets are
located inside China, the remaining $1.020 in assets are located in the United
States. Since 1994, the exchange rate for Renminbi against the United States
dollar has remained relatively stable; with an exchange rate approximately
RMB8.28 to US$1.00. On July 21, 2005, China announced a revaluation of RMB and
dropped its peg to the US dollar. China is planning to move to a managed float
against a basket of currencies. The exchange rate has been adjusted to
approximately RMB7.8041 to US$1.00. The Chinese Renminbi has increased slightly
in value as compared to the U.S. dollar. However, there can be no assurance that
Renminbi will not be subject to devaluation. We may not be able to hedge
effectively against Renminbi devaluation, so there can be no assurance that
future movements in the exchange rate of Renminbi and other currencies will not
have an adverse effect on our financial condition.

ITEM 8.  FINANCIAL STATEMENTS.

The information required by Item 7 appears after the signature page to this
report.

ITEM 9A. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
         FINANCIAL DISCLOSURES

NONE

                                       15
<PAGE>

ITEM 9B. CONTROLS AND PROCEDURES

We have no formal audit committee. However, our entire Board of Directors (the
"Board") serves in the capacity of the audit committee. In discharging its
oversight responsibility as to the audit process, the Board obtained from the
independent auditors a formal written statement describing all relationships
between the auditors and us that might bear on the auditors' independence as
required by Independence Standards Board Standard No. 1, "Independence
Discussions with Audit Committees." The Board discussed with the auditors any
relationships that may impact their objectivity and independence, Including fees
for non-audit services, and satisfied itself as to the auditors' independence.
The Board also discussed with management and the independent auditors the
quality and adequacy of its internal controls. The Board reviewed with the
independent auditors their management letter on internal controls.

The Board discussed and reviewed with the independent auditors all matters
required to be discussed by auditing standards generally accepted in the United
States of America, including those described in Statement on Auditing Standards
No. 61, as amended, "Communication with Audit Committees". The Board reviewed
the audited consolidated financial statements of the Company as of and for the
year ended December 31, 2005 with management and the independent auditors.
Management has the responsibility for the preparation of the Company's financial
statements and the independent auditors have the responsibility for the
examination of those statements. Based on the above-mentioned review and
discussions with the independent auditors and management, the Board of Directors
approved the Company's audited consolidated financial statements and recommended
that they be included in its Annual Report on Form 10-KSB for the year ended
December 31, 2005, for filing with the Securities and Exchange Commission.

As of the end of the period covered by this report (the "Evaluation Date"), we
carried out an evaluation in accordance with the requirements of the Chinese
auditing standards as well as the applicable rules in the United States. The
Company had set up an audit group, which consisted of the Chief Executive
Officer, Chief Financial Officer, one of the members of the board of directors
and two executives (including the manager) from our internal audit department.
This audit group is under the supervision of our Chief Executive Officer and
Chief Financial Officer. The Company's audit group evaluated the effectiveness
of the design and operation of our disclosure controls and procedures as defined
in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as
amended (the "Exchange Act") of our Annual Report on Form 10-K before it was
filed with the Securities and Exchange Commission. The audit group made their
evaluation pursuant to Rule 13a-15 under the Exchange Act to the maximum
possible extent and to the best knowledge of the audit group. Based upon our
evaluation, our Chief Executive Officer and our Chief Financial Officer
concluded that, as of the Evaluation Date, our disclosure controls and
procedures were effective and basically sound in all material aspects under Rule
13a-15.

However, given the fact that our major operations are located China, the Company
and the audit group consistently make efforts to coordinate the evolving control
and disclosure environment in China with the regulatory environment in the
United States. The Company has identified this aspect as an area for improvement
and is taking measures to train its staff for better performance.

The Company anticipates that it will be fully compliant with Section 404 of the
Sarbanes-Oxley Act of 2002 by the required date for non-accelerated filers and
it is in the process of reviewing its internal control systems in order to be
compliant with Section 404 of the Sarbanes-Oxley Act. However, at this time the
Company makes no representation that its systems of internal control comply with
Section 404 of the Sarbanes-Oxley Act.

ITEM 9C. OTHER INFORMATION.

Not applicable.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS,
         COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

The following table sets forth the names, ages, principal offices and positions
and the date each such person became a director or executive officer. Executive
officers are elected annually by our Board of Directors. Each executive officer
holds his office until he resigns, is removed by the Board or his successor is
elected and qualified. Directors are elected annually by our stockholders at the
annual meeting. Each director holds his office until his successor is elected
and qualified or his earlier resignation or removal.

                                       16
<PAGE>

                                                           DATE OF
NAME AND PRINCIPAL POSITION                     AGE      APPOINTMENT
---------------------------                     ---      -----------
YanBiao Bai, Chairman, CEO and President         46          2003

Dr. Lei (Larry) Liu,
Former CEO and Director                          51          2001

Xue Bu, Director, Treasurer & Chief
Operating Officer                                43          2005

Below are brief descriptions of the backgrounds and experiences of our current
officers and directors:

Mr. YanBiao Bai, Chairman, CEO and President

YanBiao Bai, graduated from the Second Military Medical University in 1984,
receiving a legal qualification certificate, is an experienced entrepreneur and
corporate executive. Since 1999 he has served as Chairman of Shaanxi Chaoying
Group, a chain of cosmetic and personal care training schools and franchises
located in China. Since 2003, he has served as Chairman of the Board of
Directors of Cybrdi, Inc. In 2006 he assumed the role as CEO. Long interested in
Chinese traditional and modern medicine, Mr. Bai is working to apply his
marketing and management expertise to the emerging biotech field in China,
focusing on rapidly marketable products and services. Mr. Bai has been awarded
one of the Shaanxi Province "Outstanding Young Industrialist Award," among other
titles and honors.

Xue Bu, Director, Treasurer  & Chief Operating Officer

Ms. Xue Bu has served as an officer and director of Cybrdi, Inc. since February
2005. She obtained her B.S. in1986 from The Fourth Military Medical University
and an MBA degree from Xi'an Jiaotong University. Ms. Bu was the Vice President
of Beijing Chaoying Real Estate Company from 1999 to 2001. Since 2001, she has
served as the Deputy General Manager of Chaoying. Ms. Bu is the wife of YanBiao
Bai.

Dr. Lei Lu is our former chief executive officer and director of the Company.
Dr. Lu serves as the president of our US based subsidiary and is responsible for
its operations.

Since 2000, Dr. Lei Liu serves as the president and chief executive officer of
Cybrdi, Maryland. He previously served as an officer and director of the public
company. Dr. Lei Liu enjoys his more than 25 year experiences on medical
research and clinical treatment. He has since 1999 served as president of IOI
USA. He was the visiting Professor of the Lombardi Cancer Center, Georgetown
University; Dr. Liu has held previous research positions at the University Of
Virginia School Of Medicine (Hematology Division), the National Cancer Institute
(Clinical Pharmacology Department), and the Armed Services University of Health
Sciences (Department of Biometrics). He has published numerous scientific
papers, including articles in Cancer Prevention and Treatment, the Journal of
Oncology, the Practical Journal of Cancer, the International Journal of Cancer,
the Journal of Neurochemistry, Clinical Cancer Research, and Biochemical
Pharmacology. His laboratory and clinical work has spanned the fields of
oncology, immunology, protein biochemistry, cell biology, molecular biology and
experimental therapeutics. Dr. Liu received his medical training and degree at
the Second Military Medical University, Shanghai, China. He also received a
Master's degree in Public Health from the Armed Services University, Bethesda,
MD, USA.

Involvement in Certain Legal Proceedings

Except as indicated above, no event listed in Sub-paragraphs of Subparagraph (f)
of Item 401 of Regulation S-K, has occurred with respect to any of our present
executive officers or directors or any nominee for director during the past five
years which is material to an evaluation of the ability or integrity of such
director or officer.

                                       17
<PAGE>

FAMILY RELATIONSHIPS

Ms. Xue Bu, the Treasurer and Chief Operating Officer, is the wife of Yanbiao
Bai the Chairman, CEO and President.

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING REQUIREMENTS.

For companies registered pursuant to section 12(g) of the Exchange Act, Section
16(a) of the Exchange Act requires our executive officers and directors, and
persons, who beneficially own more than ten percent of our equity securities, to
file reports of ownership and changes in ownership with the Securities and
Exchange Commission. Officers, directors and greater than ten percent
shareholders are required by SEC regulation to furnish us with copies of all
Section 16(a) forms they file. To our knowledge, based solely on a review of the
copies of reports filed with the Securities and Exchange Commission, Section
16(a) filing requirements applicable to our officers, directors and greater than
ten percent beneficial owners were met during the Company's last fiscal year and
there has been no change in beneficial ownership.

All officers and directors owning shares of common stock have however recently
filed the required reports under Section 16(A) of the Act.

CODE  OF ETHICS

The Company has a Code of Business Conduct and Ethics, which is applicable to
all directors, officers and employees of the Company.

ITEM 11. EXECUTIVE COMPENSATION

SUMMARY COMPENSATION TABLE

The following table sets forth all cash compensation paid or to be paid by
Cybrdi, as well as certain other compensation paid or accrued, for each of the
last three fiscal years of our company to each named executive officer.

                           SUMMARY COMPENSATION TABLE

<TABLE>
<CAPTION>
                                                                                LONG-TERM
                                               ANNUAL COMPENSATION          COMPENSATION AWARDS
                                            --------------------------   -----------------------
                                                                         RESTRICTED   SECURITIES
                                                                           STOCK      UNDERLYING      ALL OTHER
NAME AND PRINCIPAL POSITION     YEAR           SALARY         BONUS        AWARD       OPTIONS      COMPENSATION
---------------------------     ----        -----------    -----------  -----------  -----------    ------------
<S>                             <C>         <C>            <C>          <C>          <C>            <C>
YanBiao Bai, Chairman, CEO      2006        $   -0-        $   -0-      $   -0-      $    -0-       $    -0-
and President                   2005        $   -0-        $   -0-      $   -0-      $    -0-       $    -0-
                                2004        $   -0-        $   -0-      $   -0-      $    -0-       $    -0-

Dr. Lei Liu, Director           2006        $80,000        $   -0-      $   -0-      $   -0-        $    -0-
Pres:  Cybrdi Maryland          2005        $60,000        $   -0-      $   -0-      $   -0-        $    -0-
Xue Bu, Director, Treasurer &   2004        $60,000        $   -0-      $   -0-      $   -0-        $    -0-
Chief Operating Officer         2005        $ 4,500        $   -0-      $   -0-      $   -0-        $    -0-
                                2004        $ 4,500        $   -0-      $   -0-      $   -0-        $    -0-
                                2003        $ 4,500        $   -0-      $   -0-      $   -0-        $    -0-

Marshall Kass, Former Chairman  2006        $   -0-        $   -0-      $   -0-      $    -0-       $    -0-
and Former CEO and Director     2005        $   -0-        $   -0-      $   -0-      $    -0-       $    -0-
                                2004        $98,000        $   -0-      $   -0-      $    -0-       $    -0-
</TABLE>

Since the merger with Certron in November 2004, no former director of the
Company has received any type of compensation solely by virtue of his position
as a director.

                                       18
<PAGE>

EMPLOYEE STOCK OPTION PLAN

None

COMPENSATION OF INDEPENDENT DIRECTORS

None

EMPLOYMENT AGREEMENTS

There are no written employment agreements with any of the Company's officers.

Mr. Bai has agreed to serve as the Company's president and chief executive
officer without compensation. There can be no assurance that he will continue to
serve as our president and chief executive officer without receiving any type of
compensation. Any compensation to be paid to Mr. Bai in the future will first be
set by our Board of Directors. Notwithstanding the foregoing, Mr. Bai has agreed
that any request for compensation on a going forward basis will not exceed
$100,000 without the consent of the Company's Board of Directors and the
shareholders.

Lei Liu has received an annual compensation of $80,000 and $60,000 for 2006 and
2005.

Xue Bu receives an annual compensation of $4,500. She will continue to receive
this salary in 2007. However, the Board of Directors reserves the right to
increase this compensation level in their sole and absolute discretion.

No compensation has been paid to any director solely in connection with their
role as a director.

BENEFITICAL OWNERSHIP OF OFFICERS AND DIRECTORS

The following table sets forth, as of April 1, 2006 information with respect to
the beneficial ownership of our common stock by (i) persons known by us to
beneficially own more than five percent of the outstanding shares, (ii) each
director, (iii) each executive officer and (iv) all directors and executive
officers as a group. As of April 1, 2006, there were issued and outstanding
50,456,567 shares of Common Stock. There are no outstanding options or warrants.

NAME OF OFFICER                                                   PERCENTAGE OF
OR DIRECTOR           TITLE        TITLE OF CLASS  NO. OF SHARES    OWNERSHIP
---------------       -----        --------------  -------------  -------------
YanBiao Bai    Chairman/CEO/Pres       Common       9,156,397(1)     18.15%

Lei Liu        Director                Common       6,234,766(2)     12.36%

Xue Bu         COO/Treasurer/Dir       Common               0

All officers
and directors
as a group
(3 people)                             Common      15,391,163        30.50%

----------
(1) Represents shares held by Shanxi Chaoying Beauty & Cosmetic Group of which
    Mr. Bai is the president.

(2) Includes 4,370,462 shares issued to Immuno-Oncogenomics, Inc., an affiliated
    entity of Lei Liu, and 1,864,304 shares which will be owned individually by
    Lei Liu.

                                       19
<PAGE>

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTION

Not applicable.

ITEM 13. EXHIBITS

(a)      Exhibits

         3.1      Articles of Incorporation of Registrant, as amended
                  (incorporated by reference to Exhibit 3.1 to Registrant's
                  Annual Report of from 10-K for the year ended October 31, 1981
                  and Exhibit "A" and Exhibit "B" to Registrant's Proxy
                  Statement dated February 17, 1988).

         3.2      By-Laws of Registrant, as amended (incorporated by reference
                  to Exhibit 3.2 to Registrant's Quarterly Report on form 10-Q
                  for the quarter ended April 30, 1989).

         *3.3     Amended Articles of Incorporation as amended increasing the
                  number of authorized shares filed as an exhibit to Form 8-k
                  filed February 15, 2005.

         *3.4     Articles of Merger filed with the Maryland Secretary of State
                  filed as an exhibit to Form 8-k filed February 15, 2005.

         *3.5     Amendment to Articles of Incorporation changing name to
                  Cybrdi, Inc. filed as an exhibit to Form 8-k filed April 6,
                  3005.

         *10.1    Registrant's Executive Stock Option Plan (incorporated by
                  reference to Exhibit "B" to Registrant's Proxy Statement dated
                  February 21, 1989).

         *10.2    Amendment to Registrant's 1989 Stock Option Plan (incorporated
                  by reference to Exhibit 10.5 to Registrant's Annual Report on
                  Form 10-K for the year ended October 31, 1995).


         *10.3    Amendment to Registrant's Executive Stock Option Plan
                  (incorporated by reference to Exhibit 10.1 to Registrant's
                  Quarterly Report on Form 10Q for the quarter ended April 30,
                  2001).

         *10.4    Form of Indemnification Agreement between Registrant and its
                  Directors and selected officers and agents (incorporated by
                  reference to Exhibit "C" to Registrant's Proxy Statement dated
                  February 17, 1988).

         *10.5    Employment Agreement effective as of November 1, 1993 between
                  Registrant and Marshall I. Kass (incorporated by reference to
                  Exhibit 10.1 to Registrant's Quarterly Report on Form 10-Q for
                  quarter ended January 31, 1994).

         *10.6    Amendment to Employment Agreement between Registrant and
                  Marshall I. Kass dated November 1, 1998 (incorporated by
                  reference to Exhibit 10.8 to Registrant's Annual Report on
                  Form 10-K for the year ended October 31, 1998).

         *10.7    Agreement and Plan of Merger among Certron Corporation,
                  Certron Acquisition Corp. and Cybrdi, Inc. filed as an exhibit
                  to the Company's Form 8-k filed February 15, 2005.

         31.1     Rule 13(a)-14(a)/15(d)-14(a) Certification

         31.2     Rule 13(a)-14(a)/15(d)-14(a) Certification

         32.1     Certification Under Section 906 of the Sarbanes-Oxley Act of
                  2002

         32.2     Certification Under Section 906 of the Sarbanes-Oxley Act of
                  2002
----------
*   Previously filed

(b)      There were no reports filed on Form 8-k during the fourth quarter of
         the Company's fiscal year.

                                       20
<PAGE>

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Audit Fees

The aggregate fees billed for each of the last two years for professional
services rendered by the principal accountant for our audits of our annual
financial statements and interim reviews of our financial statements included in
our Form 10-KSBs and 10-QSBs or services that are normally provided by the
accountant in connection with statutory and regulatory filings or engagements
for those years were approximately:

         2006     $67,000  was billed  by MS Group CPA LLC

         2005:    $61,500 Bagell, Josephs LLC

Audit Related Fees

The aggregate fees billed in each of the last two years for the assurance and
related services provided by the principal accountant that are not reasonably
related to the performance of the audit or review of the Company's financial
statements and are not reported in paragraph (1) were approximately:

         2006     $7,500 was paid to Weinberg

         2005:    $0

Tax Fees

The aggregate fees billed in each of the last two years for the professional
services rendered by the principal accountant for tax compliance, tax advice and
tax planning were approximately:

         2006     $3,500

         2005     $3,500

We incurred these fees due to the preparation of our tax returns.

All Other Fees

The aggregate fees billed in each of the last two years for the products and
services provided by the principal accountant, other than the services reported
in paragraph (1) were approximately:

         2006:    $0

         2005:    $0

                                       21
<PAGE>

                                   SIGNATURES


Pursuant to the requirements of Section 13 or 15(d) of the Securities and
Exchange Act, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Date:  April 16, 2007                 By: /s/      YanBiao Bai
                                          --------------------------------------
                                          By:    YanBiao Bai
                                          Title: Chief Executive Officer
                                                 and Director

Pursuant to the requirements of the Securities and Exchange Act of 1934, this
Report has been signed below by the following person on behalf of the Registrant
and in the capacities and on the dates indicated.

NAME AND PRINCIPAL POSITION                 SIGNATURE                  DATE
---------------------------                 ---------                  ----
YanBiao Bai, Chairman, CEO and President    /s/YanBaio Bai        April 16, 2007

Larry Liu                                                         April 17, 2007

Xue Bu, Director, Treasurer & COO           /s/Xue Bu             April 17, 2007

                                       22

<PAGE>

                           CYBRDI, INC. AND SUBSIDIARY

                        CONSOLIDATED FINANCIAL STATEMENTS

                           DECEMBER 31, 2006 AND 2005



<PAGE>
                           CYBRDI, INC. AND SUBSIDIARY

                                    CONTENTS
PAGE
----

F-2            REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

F-3            CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2006 AND 2005

F-4            CONSOLIDATED STATEMENTS OF OPERATIONS
               FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005

F-5            CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
               FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005

F-6            CONSOLIDATED STATEMENTS OF CASH FLOWS
               FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005

F-7 TO F-18    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                      F-1
<PAGE>
            REPORET OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors
and Stockholders
Cybrdi, Inc. (f/k/a Certron Corporation)

We have audited the accompanying consolidated balance sheets of Cybrdi, Inc.
(f/k/a Certron Corporation.) as of December 31, 2006 and 2005 and the related
consolidated statements of income and comprehensive income, changes in
stockholders' equity, and cash flows for the years then ended. These
consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audit.

We conducted our audit in accordance with standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the consolidated financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall consolidated financial statement
presentation. We believe that our audit provide a reasonable basis for our
opinion.

In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Cybrdi, Inc. (f/k/a
Certron Corporation.) as of December 31, 2006 and 2005 and the results of its
consolidated operations, changes in stockholders' equity, and cash flows for the
years then ended in conformity with accounting principles generally accepted in
the United States of America.

MS Group CPA LLC

MS Group CPA LLC
Edison, New Jersey
March 19, 2007


                                      F-2
<PAGE>
                          CYBRDI, INC. AND SUBSIDIARY
                          CONSOLIDATED BALANCE SHEETS

                                                             DECEMBER 31,
                                                      -------------------------
                 ASSETS                                   2006          2005
                                                      -----------   -----------
CURRENT ASSETS
     Cash and equivalents                             $   782,899   $ 4,206,695
     Accounts receivable                                   37,382       360,503
     Inventories                                          366,161       263,634
     Loan to unaffiliated company                       3,241,886            --
     Other receivables and prepaid expenses               200,384        96,626
                                                      -----------   -----------
TOTAL CURRENT ASSETS                                    4,628,712     4,927,458
PROPERTY, PLANT AND EQUIPMENT, NET                        505,714       553,382
INTANGIBLE ASSETS, NET                                    519,415       581,593
DEFERRED TAX ASSETS                                            --        41,199
                                                      -----------   -----------

TOTAL ASSETS                                            5,653,841     6,103,632
                                                      ===========   ===========

      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
     Accounts payable and accrued expenses                133,463        34,118
     Other payables                                        31,508        51,193
     Amount due to stockholders/officers                  205,218       645,021
                                                      -----------   -----------
TOTAL CURRENT LIABILITIES                                 370,189       730,332

MINORITY INTERESTS                                      1,124,557     1,149,158
                                                      -----------   -----------

TOTAL LIABILITIES                                       1,494,746     1,879,490
                                                      -----------   -----------
STOCKHOLDERS' EQUITY
     Preferred Stock, $1.00 per value,
        500,000 shares authorized,
        zero shares issued and outstanding                                   --
     Common Stock, no par value,
        150,000,000 shares authorized,
        50,456,569 shares issued and
        outstanding as of December 31, 2006 and 2005                         --
     Additional paid-in capital                         3,601,932     3,601,932
     Reserve funds                                        336,885       336,885
     Accumulated (deficit) / retained earnings            (12,639)      174,416
     Accumulated other comprehensive income               232,917       110,909
                                                      -----------   -----------
TOTAL STOCKHOLDERS' EQUITY                              4,159,095     4,224,142

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY            $ 5,653,841   $ 6,103,632
                                                      ===========   ===========

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                      F-3
<PAGE>
                           CYBRDI, INC AND SUBSIDIARY
                     CONSOLIDATED STATEMENTS OF OPERATIONS

                                               FOR YEARS ENDED DECEMBER 31,
                                               ------------   -------------
                                                   2006           2005
                                               ------------   ------------
Revenue
      Products                                 $    441,007   $  1,173,171
      Service rendered                              101,279        254,628
                                               ------------   ------------
         Total revenue                              542,286      1,427,799
                                               ------------   ------------
Cost of Sales
      Products                                      257,782        244,331
      Service rendered                               16,432         35,507
                                               ------------   ------------
        Total cost of sales                         274,214        279,838
                                               ------------   ------------
Gross Profit                                        268,072      1,147,961
                                               ------------   ------------
Operating Expenses:
      Selling and distribution expenses             107,684        100,173
      General and administrative expenses           586,386        581,835
                                               ------------   ------------
Total Operating Expenses                            694,070        682,008
                                               ------------   ------------

(Loss) Income from Operations                      (425,998)       465,953
                                               ------------   ------------
Other Income/(Expense)
      Interest income                               173,072         30,408
      Other income/(expense), net                    41,270       (317,127)
                                               ------------   ------------
Total Other Income (Expense)                        214,342       (286,719)
                                               ------------   ------------

(Loss) Income before Income Taxes                  (211,656)       179,234
Income Taxes Expenses                                    --        (48,097)
                                               ------------   ------------
(Loss) Income before Minority Interest             (211,656)       131,137
Minority (Loss)/Interest                            (24,601)       126,009
                                               ------------   ------------

Net (Loss) Income                              $   (187,055)  $      5,128

Other Comprehensive Income (Loss):
Foreign Currency Translation gain                   122,008        110,653
                                               ------------   ------------

Comprehensive (Loss) Income                    $    (65,047)  $    115,781
                                               ============   ============

Net (Loss) Income Per Common Share
      Basic and Diluted                        $      (0.00)  $       0.00
                                               ============   ============

Weighted Average Number of Shares Outstanding
      Basic and Diluted                          50,456,569     50,456,569
                                               ============   ============

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                      F-4
<PAGE>
                          CYBRDI, INC. AND SUBSIDIARY
           CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
                 FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005

<TABLE>
<CAPTION>
                                                                                      RETAINED       ACCUMULATED
                               COMMON STOCK             ADDITIONAL                    EARNINGS /        OTHER
                      ----------------------------       PAID-IN       RESERVE       ACCUMULATED    COMPREHENSIVE
                      NO OF SHARES        AMOUNT         CAPITAL         FUND          DEFICIT          INCOME          TOTAL
                      -------------    -----------     -----------    -----------    -----------    -------------   -----------
<S>                    <C>             <C>             <C>            <C>            <C>             <C>            <C>
Balance as of
 December 31, 2004      30,210,000       3,021,000         572,232        240,416        265,757             256      4,099,661

Recapitalization       (30,210,000)     (3,021,000)      3,021,000             --             --              --             --

Merged with
 Cybrdi Maryland        50,456,569              --              --             --             --              --             --

Net income                      --              --              --             --          5,128              --          5,128

Imputed rent
 expenses                       --              --           8,700             --             --              --          8,700

Appropriation of
  Reserve funds                 --              --              --         96,469        (96,469)             --             --

Foreign currency
   translation gain             --              --              --             --             --         110,653        110,653
                       -----------     -----------     -----------    -----------    -----------     -----------    -----------

Balance as of
 December 31, 2005      50,456,569     $        --     $ 3,601,932    $   336,885    $   174,416     $   110,909    $ 4,224,142

Net income                      --              --              --             --       (187,055)             --       (187,055)

Foreign currency
   translation gain             --              --              --             --             --         122,008        122,008
                       -----------     -----------     -----------    -----------    -----------     -----------    -----------

Balance as of
 December 31, 2006      50,456,569     $        --     $ 3,601,932    $   336,885    $   (12,639)    $   232,917    $ 4,159,095
                       ===========     ===========     ===========    ===========    ===========     ===========    ===========
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                      F-5
<PAGE>
                          CYBRDI, INC. AND SUBSIDIARY
                     CONSOLIDATED STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                          FOR YEARS ENDED DECEMBER 31,
                                                          ----------------------------
                                                              2006            2005
                                                          -----------    -----------
<S>                                                       <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
    Net (Loss) Income                                     $  (187,055)   $     5,128
    Adjustments to Reconcile Net (Loss)
     Income to Net Cash Provided by
     Operating Activities:
         Depreciation and amortization                        164,857        196,809
         Loss on disposal of fixed assets                       3,167             --
         Minority interest                                    (24,601)       126,009
         Imputed rental income                                     --          8,700
    Changes in Operating Assets and Liabilities:
         Deferred tax assets                                   41,199             (2)
         Accounts receivable                                  374,028        (99,338)
         Inventories                                          (90,454)         7,764
         Other receivable and prepaid expenses                (97,151)       (87,159)
         Accounts payable and accrued expenses                 94,944         33,220
         Other payables                                       (20,724)        (9,216)
                                                          -----------    -----------
    Net Cash Provided by Operating Activities                 258,210        181,915
                                                          -----------    -----------
CASH FLOWS FROM INVESTING ACTIVITIES
         Purchase of property, plant and equipment            (23,335)       (30,173)
         Loan to unaffiliated companies                    (3,241,886)            --
                                                          -----------    -----------
    Net Cash Used in Investing Activities                  (3,265,221)       (30,173)
                                                          -----------    -----------
CASH FLOWS FROM FINANCING ACTIVITIES
         Proceeds from shareholders/officers                   14,849         77,953
         Payment to shareholders/officers                    (454,652)            --
                                                          -----------    -----------
    Net Cash (Used in) Provided by Financing Activities      (439,803)        77,953
                                                          -----------    -----------
NET DECREASE IN CASH AND EQUIVALENTS
    Net (Decrease) Increase in Cash and Equivalents        (3,446,814)       229,695
    Effect of Exchange Rate
      Changes on Cash and Equivalents                          23,018         77,294
    Cash and Equivalents, at Beginning of Period            4,206,695      3,899,706
                                                          -----------    -----------

    Cash and Equivalents, at End of Period                $   782,899    $ 4,206,695
                                                          ===========    ===========
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION
    Interest paid                                         $        --    $        --
                                                          ===========    ===========
    Income taxes paid                                     $    13,463    $        --
                                                          ===========    ===========
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                      F-6
<PAGE>
                          CYBRDI, INC. AND SUBSIDIARY
                   NOTES TO CONSOLIDATED FINANICAL STATEMENTS
                 FOR THE YEARS ENDED DECEMBER 31, 2006 AND 2005

1.       ORGANIZATION AND PRINCIPAL ACTIVITIES

         Cybrdi, Inc. (f/k/a Certron Corporation) (the "Company" or "Cybrdi")
         was incorporated on August 1, 1966, under the laws of the State of
         California. Until around June 2004, the Company's business consisted
         primarily of the distribution of magnetic media products, primarily
         blank audio and video cassettes. Due to continuing intense price
         competition and technological changes in the marketplace for its
         products, the Company lost its remaining significant customers and
         disposed of or wrote off its remaining inventory. As a result of these
         occurrences, the Company concluded that its audio and videotape
         businesses were no longer viable and some of its product lines were
         obsolete and the Company placed its emphasis on attempting to find a
         buyer for the Company.

         In November 2004, the Company, through Certron Acquisition Corp., a
         newly formed Maryland corporation and wholly-owned subsidiary of the
         Company ("Acquisition Sub") acquired all the ownership interest in
         Cybrdi, Inc., a privately held company incorporated in the State of
         Maryland ("Cybrdi Maryland"). The Company acquired Cybrdi Maryland in
         exchange for 47,328,263 shares of common stock of the Company.
         Subsequent to the merger, the former shareholders of Cybrdi Maryland
         own approximately 93.8% of the outstanding shares of the Company's
         common stock. As a result of the ownership interests of the former
         shareholders of Cybrdi Maryland, for financial statement reporting
         purposes, the merger was treated as a reverse acquisition, with Cybrdi
         Maryland deemed the accounting acquirer and Centron Corporation deemed
         the accounting acquiree. Historical information of the surviving
         company is that of Cybrdi Maryland.

         Cybrdi Maryland was established in 2001 to acquire an interest in
         biogenetic products commercialization and related services entities in
         Asia. On March 5, 2003, Cybrdi Maryland acquired 80% interest of the
         Shaanxi Chao Ying Biotechnology Co., Ltd. ("Chaoying Biotech"), a
         sino-foreign equity joint venture established in July 2000 in the
         People's Republic of China ("PRC"), through the exchange of 99% of the
         Company's shares to the existing shareholders of Chaoying Biotech. For
         financial statement reporting purposes, the merger was treated as a
         reverse acquisition, with Chaoying Biotech deemed the accounting
         acquirer and Cybrdi Maryland deemed the accounting acquiree.

         Chaoying Biotech is a sino-foreign equity joint venture between Shaanxi
         Chao Ying Personal Care Group Ltd. (the "Chinese Partner", a PRC
         corporation) and Immuno-OncoGenomics Inc. (the "Foreign Partner", a USA
         corporation). The joint venture agreement has a 15 year operating
         period starting from its formation in July 2000 and is extendable upon
         mutual consent of both partners. The principal activities of Chaoying
         Biotech are research, manufacture and sale of various high-quality
         tissue arrays and the related services in the PRC.

                                      F-7
<PAGE>

         Most of the Company's activities are conducted through Chaoying
         Biotech. Chaoying Biotech, with its principal operations located in
         China, aims to take advantage of China's abundant scientific talent,
         low wage rates, less stringent biogenetic regulation, and the huge
         genetic population as it introduces its growing list of tissue micro
         array products.

         On February 10, 2005, the Company completed the merger with Cybrdi
         Maryland and changed its name to Cybrdi, Inc.

2.       BASIS OF PRESENTATION

         The accompanying consolidated financial statements are prepared in
         accordance with generally accepted accounting principles in the United
         States of America ("US GAAP"). This basis of accounting differs from
         that used in the statutory accounts of the Subsidiary, which were
         prepared in accordance with the accounting principles and relevant
         financial regulations applicable to enterprises with foreign investment
         in the PRC ("PRC GAAP"). Necessary adjustments were made to the
         Subsidiary's statutory accounts to conform to US GAAP to be included in
         these consolidated financial statements.

3.       SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

         (a)      Principle of consolidation - The accompanying consolidated
                  financial statements present the financial position, results
                  of operations and cash flows of the Company and all entities
                  in which the Company has a controlling voting interest. The
                  consolidated financial statements also include the accounts of
                  any variable interest entities in which the Company is
                  considered to be the primary beneficiary and such entities are
                  required to be consolidated in accordance with accounting
                  principles generally accepted in the United States ("US
                  GAAP"). The consolidated financial statements include the
                  financial statements of Cybrdi, Inc. and its subsidiary. All
                  significant intercompany transactions and balances are
                  eliminated in consolidation.

         (b)      Use of estimates - The preparation of financial statements
                  requires management to make estimates and assumptions that
                  affect the reported amounts of assets and liabilities and
                  disclosure of contingent assets and liabilities at the date of
                  the financial statements and the reported amounts of revenues
                  and expenses during the reported period. Actual results could
                  differ from those estimates.

         (c)      Cash and equivalents- For financial reporting purposes, the
                  Company considers all highly liquid investments purchased with
                  an original maturity of three months or less to be cash
                  equivalents.

                                      F-8
<PAGE>

         (d)      Inventories- Inventories are stated at the lower of cost or
                  market. Cost of raw materials is determined on the basis of
                  first in first out method ("FIFO"). Finished goods are
                  determined on the weighted average basis and are comprised of
                  direct materials, direct labor and an appropriate proportion
                  of overhead.

         (e)      Property, plant and equipment - Property, plant and equipment
                  are stated at cost less accumulated depreciation and
                  amortization. Depreciation on property, plant and equipment is
                  calculated on the straight-line basis to write off the cost of
                  assets over their respective estimated useful lives. Leasehold
                  improvements are amortized over the estimated useful life of
                  the improvement or the lease term, whichever is shorter.
                  Estimated useful lives of the property, plant and equipment
                  are as follows:

                           Buildings                        20 years
                           Plant and machinery              10 years
                           Motor vehicles                   10 years
                            Office equipment 5 years
                           Leasehold improvements           Lower of term of
                                                            lease or 5 years
                           Software - website               3 years

                  The cost and related accumulated depreciation of assets sold
                  or otherwise retired are eliminated from the accounts and any
                  gain or loss is included in the statements of operations. The
                  cost of maintenance and repairs is charged to income as
                  incurred, whereas significant renewals and betterments are
                  capitalized.

                  Long-term assets of the Company are reviewed annually as to
                  whether their carrying value has become impaired, pursuant to
                  the guidelines established in Statement of Financial
                  Accounting Standards ("SFAS") No. 144, "Accounting for the
                  Impairment or Disposal of Long-Lived Assets". The Company also
                  re-evaluates the periods of amortization to determine whether
                  subsequent events and circumstances warrant revised estimates
                  of useful lives.

         (f)      Accounts and other receivables - Accounts and other
                  receivables are recognized and carried at original invoice
                  amount less allowance for any uncollectible amounts. An
                  estimate for doubtful accounts is made when collection of the
                  full amount is no longer probable. As of December 31, 2006 and
                  2005, the company has not recorded an allowance for
                  uncollectible accounts.

         (g)      Research and development costs - Research and development
                  costs are charged to operations when incurred and are included
                  in operating expenses. The amounts charged in 2006 and 2005
                  were $7,420 and $7,936, respectively.

                                      F-9
<PAGE>

         (h)      Advertising costs - Advertising costs are charged to
                  operations when incurred and are included in operating
                  expenses. Advertising expenses were $17,355 and $27,082 for
                  the years ended December 31, 2006 and 2005, respectively. (i)
                  In-kind contribution - From inception through December 2005, a
                  related party provided office space and utilities to the
                  Company's subsidiary in PRC. The Company was not required to
                  pay for its use of the facilities. Accordingly, the Company
                  recognized $8,700 of expenses during 2005, for these
                  contributed items with an offsetting increase in additional
                  paid-in capital. Management estimated the value of the
                  contributed items.

         (j)      Fair value of financial instruments - The carrying amounts of
                  cash and equivalents, accounts receivable, inventories, loan
                  to unaffiliated company, other receivables and prepaid
                  expenses, accounts payable and accrued expenses, other
                  payables, and amounts due to shareholders approximate fair
                  value due to the short-term maturities of the assets and
                  liabilities.

         (k)      Revenue recognition - Revenue represents the invoiced value of
                  goods sold recognized upon the delivery of goods to customers
                  and service income is recognized when services are provided.
                  Deferred revenue represents the undelivered portion of
                  invoiced value of goods sold to customers. Sales transactions
                  not meeting all the conditions of the full accrual method are
                  accounted for using the deposit method of accounting. Under
                  the deposit method, all costs are capitalized as incurred, and
                  payments received from the buyer are recorded as customer
                  deposits.

         (l)      Foreign currency translation - The accompanying consolidated
                  financial statements are presented in United States dollars.
                  The functional currency of the Company's PRC subsidiary is
                  Renminbi (RMB). The financial statements are translated into
                  United States dollars from RMB at year-end exchange rates as
                  to assets and liabilities and weighted average exchange rates
                  as to revenues and expenses. Capital accounts are translated
                  at their historical exchange rates when the capital
                  transactions occurred.

                  The RMB is not freely convertible into foreign currency and
                  all foreign exchange transactions must take place through
                  authorized institutions. No representation is made that the
                  RMB amounts could have been, or could be, converted into USD
                  at the rates used in translation.

         (m)      Income Taxes -Income taxes are provided for the tax effects of
                  transactions reported in the financial statements and consist
                  of taxes currently due plus deferred taxes related primarily
                  to differences between the basis of assets and liabilities for
                  financial and income tax reporting. The deferred tax assets
                  and liabilities represent the future tax return consequences
                  of those differences, which will either be taxable or
                  deductible when the assets and liabilities are recovered or
                  settled. Deferred taxes also are recognized for operating
                  losses that are available to offset future federal and state
                  income taxes.

                                      F-10
<PAGE>

         (n)      Comprehensive income (loss) - SFAS No. 130, "Reporting
                  Comprehensive Income", established standards for the reporting
                  and display of comprehensive income, its components and
                  accumulated balances in a full set of general purpose
                  financial statements. SFAS No. 130 defines comprehensive
                  income to include all changes in equity except those resulting
                  from investments by owners and distributions to owners. Among
                  other disclosures, SFAS No. 130 requires that all items that
                  are required to be recognized under current accounting
                  standards as components of comprehensive income be reported in
                  a financial statement that is presented with the same
                  prominence as other financial statements. The Company's only
                  current component of comprehensive income is the foreign
                  currency translation adjustment.

         (o)      Intangible assets - Intangible assets include a patent.
                  Effective January 1, 2002, with the adoption of SFAS No. 142,
                  intangible assets with a definite life are amortized on a
                  straight-line basis. The patent is being amortized over its
                  estimated life of 10 years. Intangible assets with a definite
                  life are tested for impairment whenever events or
                  circumstances indicate that a carrying amount of an asset
                  (asset group) may not be recoverable. An impairment loss would
                  be recognized when the carrying amount of an asset exceeds the
                  estimated undiscounted cash flows used in determining the fair
                  value of the asset. The amount of the impairment loss to be
                  recorded is calculated by the excess of the asset's carrying
                  value over its fair value. Fair value is generally determined
                  using a discounted cash flow analysis. Costs related to
                  internally develop intangible assets are expensed as incurred.

         (p)      Government grants - Government grants and awards given to the
                  Company after successful completion of product development
                  projects are recognized as income upon receipts of the awards.
                  The government grants were $12,168 and $56,263 for the years
                  ended December 31, 2006 and 2005.

4.       TAXATION

         (a)      Corporation Income Tax

                  The operations in the United States of America have had
                  operational losses since inception. The possible future
                  deferred tax benefit arise from the net operating loss carry
                  forward has been fully offset by a full valuation allowance.

         (b)      Corporation Income Tax ("CIT") of the Company's subsidiary in
                  PRC

                  In accordance with the relevant tax laws and regulations of
                  the PRC, the Company's subsidiary is entitled to full


                                      F-11
<PAGE>

                  exemption from CIT for the first two years and a 50% reduction
                  in CIT for the next three years, commencing from the first
                  profitable year after offsetting all tax losses carried
                  forward from the previous five years. As 2003 was the
                  Company's first profitable year, the Company was entitled to a
                  full exemption from CIT for the year starting 2003. The
                  Company begins to record 50% CIT provision from the first
                  quarter of 2005. Effective tax rate is approximately 7.5% for
                  the year ended December 31, 2005 and 2006.

                  The tax effects of temporary differences that give rise to
                  significant portions of deferred tax assets are $0 and $41,199
                  as of December 31, 2006 and 2005. There was no valuation
                  allowance as of December 31, 2006 and 2005.

5.       PROPERTY, PLANT AND EQUIPMENT

         Property, plant and equipment consist of the following as of
December 31:
                                             2006         2005
                                          ----------   ----------
         At cost:-
              Buildings                   $   66,967   $   64,758
              Plant and machinery            413,175      395,741
              Motor vehicles                 275,397      254,004
              Office equipments               90,193       94,598
              Leasehold improvement          234,243      226,520
              Software - website              86,826       83,963
                                          ----------   ----------
                                           1,166,801    1,119,584
         Less: Accumulated depreciation
           and amortization:                 661,087      566,202
                                          ----------   ----------

         Net book value                   $  505,714   $  553,382
                                          ==========   ==========

         Depreciation and amortization expenses for the years ended December 31,
         2006 and 2005 were $84,579 and $133,979, respectively.

6.       INVENTORIES

         Inventories consist of the following as of December 31:

                                          2006       2005
                                        --------   --------

                  Raw materials         $ 25,605   $ 11,249
                  Finished goods         339,447    251,911
                  Packaging materials      1,109        474
                                        --------   --------

                                        $366,161   $263,634
                                        ========   ========

                                      F-12
<PAGE>

7.       INTANGIBLE ASSETS

         Intangible assets consist of the following as of December 31:

                                                     2006       2005
                                                   --------   --------

                  Patent                           $820,082   $793,041
                  Less: Accumulated amortization    300,667    211,448
                                                   --------   --------

                                                   $519,415   $581,593
                                                   ========   ========

         Amortization expenses for the years ended December 31, 2006 and 2005
         were $80,278 and $62,830, respectively.

         Expected amortization expenses for intangible assets in the next five
         years are as follows:

                           2007                            80,278
                           2008                            80,278
                           2009                            80,278
                           2010                            80,278
                           2011                            80,278

8.       AMOUNT DUE TO STOCKHOLDERS/OFFICERS

         During the years ended December 31, 2006 and 2005,
         shareholders/officers of the Company made advances to the Company to
         assist with operations. These advances were non-interest bearing and
         have no set repayment terms. As of December 31, 2006 and 2005, the
         Company owed the shareholders/officers $205,218 and $ 645,021,
         respectively.

9.       COMMITMENTS, CONTINGENCIES, AND LEGAL PROCEEDINGS

         There is no material pending legal proceedings to which the Company is
         a party. The Company was notified by a letter dated June 2, 2000
         received June 6, 2000 that the Company may has a potential liability
         from waste disposal in the Casmalia Disposal Site at Santa Barbara
         County, California. The Company was given a choice of either signing an
         agreement that would toll the statute of limitations for eighteen (18)
         months in order to allow us to resolve any liability with the
         government without incurring costs associated with being named a
         defendant in a lawsuit, or becoming an immediate defendant in a
         lawsuit. The Company signed the tolling agreement. On November 20,
         2001, the tolling agreement was extended for an additional 18 months.
         On May 20, 2003 the tolling agreement was again extended for an
         additional 18 months and on November 24, 2004 the tolling agreement was
         again extended for additional 18 months. On June 29, 2004, the Company
         received a proposed settlement from the EPA in the amount of $21,131.
         The Company is waiting for communication from the government concerning
         payment of the proposed settlement. As of December 31, 2006 and 2005,
         the Company has accrued a sufficient amount to cover any potential
         liabilities from this matter under other payable.

                                      F-13
<PAGE>

         From inception through December 31, 2005, a related party provided free
         office space and utilities to the Company's subsidiary in PRC. During
         the years ended December 31, 2005, 2004 and 2003, the Company
         recognized $8,700 as expenses for these contributed items with an
         offsetting increase in additional paid-in capital. This arrangement was
         expired on December 31, 2005.

         The Company's subsidiary in PRC leased an office space under operating
         lease agreement from its related party for a lease term originally
         expired on December 31, 2006 had been extended to December 31, 2007.
         There is no renewal option on the lease. The rent payment under this
         operating lease was $5,017 per month (equivalent to RMB 40,000 per
         month). The future minimum rental payment as of December 31, 2006 was
         $60,204 (equivalent to RMB480,000).

         The Company leased an office space in Maryland USA under a
         month-to-month term operating lease. The rent payment under this
         operating lease was $2,180 per month.

         Total rental expense charged to operations amounted to $86,893 and
         $26,360 for each of the years ended December 31, 2006 and 2005,
         respectively.

10.      GOVERNMENT GRANT

         In 2000, the PRC Government launched the "Western Development Project"
         which part of the project included the development of 15 specifically
         named technologies and has allocated government grants to encourage the
         development of these technologies. In year 2006 and 2005, the Company
         has successfully applied and received the government grants under the
         Western Development Project amounting to $12,168 and $56,263 for the
         years ended December 31, 2006 and 2005, respectively. The government
         grant has been included in Other Income, net in the accompanying
         statements of operations and comprehensive income/ (loss).

11.      STOCKHOLDERS' EQUITY

         On February 10, 2005, the Company completed the merger with Cybrdi
         Maryland and changed its name to Cybrdi, Inc. The Company acquired
         Cybrdi Maryland in exchange for 47,328,263 shares of common stock of
         the Company. Subsequent to the merger, the former shareholders of
         Cybrdi Maryland own approximately 93.8% of the outstanding shares of
         the Company's common stock. The Company has 50,456,569 shares of common
         stock issued and outstanding after the issuance of new shares. As a
         result of the ownership interests of the former shareholders of Cybrdi
         Maryland, for financial statement reporting purposes, the merger was
         treated as a recapitalization event for Cybrdi Maryland and as a
         reverse acquisition, with Cybrdi Maryland deemed the accounting
         acquirer and Centron Corporation deemed the accounting acquiree.


                                      F-14
<PAGE>

         Historical information of the surviving company is that of Cybrdi
         Maryland.

         In 2004, the Cybrdi Maryland completed a private placement arrangement
         and had issued 5,590,645 ordinary common shares for a net proceed of
         approximately $1,006,316. In connection with this private placement,
         the company incurred a total of $491,596 legal and professional
         expenses, of which $311,113 were deferred through December 31, 2003,
         and the full amount were written off against additional paid in capital
         upon consummation of the transaction.

12.      RESERVE FUNDS

         The Company's subsidiary in PRC is required to maintain certain
         statutory reserves by appropriating from the profit after taxation in
         accordance with the relevant laws and regulations in the PRC and
         articles of association of the subsidiary before declaration or payment
         of dividends. The reserves form part of the equity of the Company.

         The appropriation to the statutory reserve and enterprise development
         reserve represent 10 percent and 5 percent of the profits after
         taxation, respectively. In accordance with the laws and regulations in
         the PRC, the appropriation to statutory reserve ceased when the
         balances of the reserve reach 50 percent of the registered capital of
         the Company.

         The reserve funds consisted of the following as of December 31:

                                            2006       2005
                                          --------   --------

         Statutory reserve                $224,590   $224,590

         Enterprise development reserve    112,295    112,295
                                          --------   --------

                                          $336,885   $336,885
                                          ========   ========

         Since the Company's subsidiary in PRC had net loss in year 2006, it did
         not require reserve additional statutory and enterprise development
         funds in year 2006.

                                      F-15
<PAGE>

13.      CONCENTRATIONS OF BUSINESS AND CREDIT RISK

         Financial Risks:

         The Company provides credit in the normal course of business. The
         Company performs ongoing credit evaluations of its customers and
         maintains allowances for doubtful accounts based on factors surrounding
         the credit risk of specific customers, historical trends, and other
         information.

         Major Customers:
         The following summarizes sales to major customers (each 10% or more of
         sale):

                           NUMBER OF        PERCENTAGE
         YEAR ENDED        CUSTOMERS        OF TOTAL
         ----------        ---------        ----------
         2006                  1              31.84%
         2005                  --                --

         Major Suppliers:

         The following summarizes purchases of raw materials from major
         suppliers (each 10% or more of purchases):

                           NUMBER OF        PERCENTAGE
         YEAR ENDED        SUPPLIERS        OF TOTAL
         ----------        ---------        ----------
         2006                  1              66.95%
         2005                  3              69.40%

         At times throughout the year, the Company may maintain certain bank
         accounts in excess of FDIC insured limits.

         Geographical Risks

         Approximately 98% of the Company's assets and approximately 50% of the
         Company's operations were in the PRC for the year ended December 31,
         2006. Accordingly, the Company's business, financial condition and
         results of operations may be influenced by the political, economic and
         legal environment in PRC, and by the general state of the PRC's
         economy. The Company's operations in PRC are subject to special
         considerations and significant risks not typically associated with
         companies in the United States. These include risks associated with,
         among others, the political, economic and legal environments and
         foreign currency exchange. The Company's results may be adversely
         affected by, among other things, changes in the political, economic and
         social conditions in PRC, and by changes in governmental policies with
         respect to laws and regulations, changes in PRC's biotechnology
         industry and regulatory rules and policies, anti-inflationary measures,
         currency conversion and remittance abroad, and rates and methods of
         taxation.

                                      F-16
<PAGE>

14.      SEGMENT REPORTING

         The Company has operations in two geographic areas, China and the
         United States. The chief Operating decision makers evaluate
         performance, make operating decisions, and allocate resources based on
         consolidated financial data. Gross profit, operating income, income
         from operation, and income taxes are not allocated to specific
         individual departments within the organization. In accordance with SFAS
         No. 131 "Disclosures about Segments of an Enterprise and Related
         Information" the Company is considered a single reportable segment. The
         Company is required to disclose certain information about revenue,
         information about geographic areas, information about major customers,
         and information about long-lived assets.

                              YEAR ENDED DECEMBER 31, 2006
                       -----------------------------------------
                       UNITED STATES      CHINA          TOTAL
                       -------------   ----------     ----------
         Revenue        $  271,279     $  271,007     $  542,286

         Long-lived
         assets         $    4,688     $1,020,441     $1,025,129

                              YEAR ENDED DECEMBER 31, 2005
                       -----------------------------------------
                       UNITED STATES      CHINA          TOTAL
                       -------------   ----------     ----------
         Revenue        $  258,028     $1,169,771     $1,427,799

         Long-lived
         assets         $   10,572     $1,165,602     $1,176,174

15.      LOAN TO UNAFFILIATED COMPANY

         Loan to unaffiliated company consists of loans to QuanYe Security
         Co.,Ltd ("QuanYe") , an unrelated People's Republic of China ("PRC")
         registered company located in Xian PRC. QuanYe is engaged in the
         pawnshop business and their primary business is offering alternative
         financing to small local companies. According to the loan agreement,
         QuanYe has received loans from Chaoying Biotech of a total amount of
         RMB29.3Million (equivalent to $3,754,437) since January 2006. As of
         December 31, 2006, the loans balance had been reduced to RMB25.3
         Million (equivalent to $3,241,886) and the details are listed as
         follows:

--------------------------------------------------------------------------------
   CONTRACT
EXECUTED DATE            LOAN AMOUNT         INTEREST   TERM   ORIGINAL DUE DATE
--------------------------------------------------------------------------------
   1/9/2006    RMB 15,000,000   $1,922,067      8%     1 year     11/16/2006
--------------------------------------------------------------------------------
   1/10/2006    RMB 8,300,000   $1,063,543      8%     1 year     11/25/2006
--------------------------------------------------------------------------------
   1/19/2006    RMB 6,000,000    $ 768,827      5%     3 months       **
--------------------------------------------------------------------------------

**  RMB1 million (equivalent to $124,740), RMB2 million (equivalent to
    $249,479), and RMB1 million (equivalent to $126,518) was repaid on April 28,
    2006, June 19, 2006, and August 16, 2006, respectively. Loan of RMB 2
    million (equivalent to $256,275) was original extended to December 31, 2006
    with an annual interest rate of 5%. In January 2007, the Company re-extends
    loan of 2 million to March 31, 2007 with an annual interest rate of 5%. F-17

                                      F-17
<PAGE>

         On October 9, 2006, Chaoying Biotech renewed the first and second loan
         agreements (RMB15 millions and RMB8.3 million) with QuanYe. Due to the
         influence of market factors, continuous increase of general and
         management cost and relatively lower profit rate of QuanYe. Chaoying
         Biotech agreed to extend the term of first and second loan for
         additional 6 months due on May 24, 2007, and adjusted its interest rate
         from 8% to 5% starting from the inception of loan to QuanYe. The
         details are listed as follows:

--------------------------------------------------------------------------------
   CONTRACT                                                            EXTENDED
RE-EXECUTED DATE             LOAN AMOUNT        INTEREST     TERM      DUE DATE
--------------------------------------------------------------------------------
11/25/2006        RMB 15,000,000   $1,922,067      5%      6 months   05/24/2007
--------------------------------------------------------------------------------
11/25/2006        RMB  8,300,000   $1,063,544      5%      6 months   05/24/2007
--------------------------------------------------------------------------------
12/31/2006        RMB  2,000,000   $  256,275      5%      3 months   03/31/2007
--------------------------------------------------------------------------------
Total             RMB 25,300,000   $3,241,886
--------------------------------------------------------------------------------

         Management believes and views QuanYe as an alternative financial
         institution and it is an optimal way to use its cash on hand. The
         regular market interest rate in the PRC is 0.72% per annum. Cybrdi
         expects to obtain higher interest income for its unused fund through
         these types of loan arrangements. However, these advances are unsecured
         and have a default risk higher than a bank deposit.

                                      F-18